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INTRODUCTION 
 
 Chronic low back pain is a significant problem. Prevalence estimates indicate that 
approximately 80% of the population will experience low back pain at some point 
(Rubin, 2007). The condition is the second leading cause of disability in the United States 
(McNeil & Binette, 2001) and after the common cold, the leading reason for sick days 
(LaBar, 1992). Overall, about 149 million work days per year are lost due to low back 
pain (Guo, Tanaka, Halperin, & Cameron, 1999). The condition leads to approximately 
100 to 200 billion dollars in losses per year, principally due to diminished wages and 
productivity (Katz, 2006). Despite advancements in treatments for chronic low back pain 
(e.g., spinal injections and stimulation, spine surgery, pain medications), the prevalence 
of the disorder has increased. One study found that the point prevalence of chronic  low 
back pain rose from 3.9% in 1992 to 10.2% in 2006—over a 160% increase in a 14 year 
period (Freburger et al., 2009).  
Low back pain patients present with meaningful rates of comorbid 
psychopathology. Von Korff et al. (2005) investigated the prevalence of mental disorders 
among individuals reporting chronic spinal pain in the National Comorbidity Survey 
Replication sample (Kessler et al., 2004) and found that individuals with chronic back 
pain were at increased risk for mood and anxiety disorders, as well as substance use 
disorders. The 12-month prevalence of mood disorders in this population was 17.5% and 
the rate for anxiety disorders was 26.5%. These rates are meaningfully higher than the 
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general population, which produces mood and anxiety disorder prevalence rates of 9.5% 
and 18.1%, respectively (Kessler, Chiu, Demler, Merikangas, & Walters, 2005).  
 The association between mental health problems and chronic pain is a well-
documented phenomena consistent with the bio-psychosocial perspective of pain 
(Gatchel, McGeary, McGeary, & Lippe, 2014; Gatchel, Peng, Peters, Fuchs, & Turk, 
2007). According to this perspective, biological, psychological, and social factors interact 
to determine the experience of pain—a model that stands in stark contrast to earlier 
medical model notions that pain was mostly the result of physiological pathology. The 
bio-psychosocial perspective advances the traditional medical model by subdividing the 
mechanisms of pain into disease and illness components. The disease is the objective 
pathophysiological disruption that may lead to pain, whereas the illness is the subjective 
perception of how the disruption affects the individual, and it is influenced by a variety of 
bio-psychosocial factors. 
 Gatchel (2004) provides examples of biological, psychological, and social factors 
influencing the perception of illness. Biological factors include pathophysiological and 
somatic influences, as well as efferent neural activity (i.e., motor activity impulses 
generated by the central nervous system) and autonomic nervous system activity. 
Afferent neural activity (i.e., impulses generated by sensory receptors that travel to the 
central nervous system) and endocrine system activity are also relevant. For example, 
hypothalamo-pituitary-adrenal (HPA) axis dysfunction has been linked to the 
development of chronic pain (Blackburn-Munro, 2004). Psychological factors include 
mood and cognitions. Finally, social factors such as social support, cultural factors, 
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activities of daily living, and medico-legal context can also influence the illness 
component of chronic pain.  
 Multi-disciplinary intervention is indicated by the bio-psychosocial perspective, 
and research indicates that it is more effective in the treatment of chronic pain outcomes 
than non-multi-disciplinary treatment controls (Guzman et al., 2001). Multi-disciplinary 
treatment typically involves various healthcare professionals, including physicians, 
nurses, psychologists, physical therapists, and case managers (Gardea & Gatchel, 2000).  
Guzman et al. (2006) conducted a systematic review of the efficacy of multi-disciplinary 
treatment of chronic low back pain. They included ten randomized clinical trials 
comparing these treatments to non-multidisciplinary controls. The authors concluded 
there was strong to moderate evidence that intensive multi-disciplinary bio-psycho-social 
rehabilitation led to improved functional ability and pain outcomes, respectively, 
compared to non-multi-disciplinary controls. For these reasons, the American College of 
Physicians and the American Pain Society recommend multi-disciplinary treatment for 
individuals with significant low back pain (Chou et al., 2007).  
 The organizations just mentioned strongly recommend that evaluations of chronic 
low back pain patients include assessments of psychosocial factors, which are described 
as stronger predictors of outcome than physical examination information, as well as 
severity and duration of pain (Chou et al., 2007). Psychological assessments should 
ideally be based on multiple sources of information, including clinical interview, 
behavioral observations, collateral report, and psychological testing (Meyer et al., 2001). 
Psychological testing in particular has demonstrated stronger validity than clinical 
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interview information and comparable validity to medical tests in a variety of settings 
(Meyer et al., 2001). The Minnesota Multiphasic Personality Inventory (MMPI; 
Hathaway & McKinley, 1943) and MMPI-2 (Butcher et al., 2001) have historically been 
the most frequently used psychological tests in chronic pain settings (Piotrowski, 1998; 
Piotrowski & Lubin, 1990).  
 
The MMPI and Chronic Pain 
 The development of the MMPI began in the late 1930’s, with the goal of creating 
a psychological test that aided in the differential diagnoses of psychiatric disorders. To 
this end, Hathaway and McKinley (1943) compiled a large item pool that they 
administered to eight different patient groups with a variety of mental disorders 
consistent with Kraepelinian nosology, as well as a nonclinical group. The clinical groups 
included patients diagnosed with Hypochondriasis, Depression, Hysteria, Psychopathic 
Deviance, Paranoia, Psychastenia, Schizophrenia, and Hypomania. An empirical keying 
approach was used to determine which items significantly differentiated each clinical 
group from the nonclinical group. Using this approach, the authors assigned items to 
eight different scales intended to predict each clinical group’s diagnosis. Two additional 
scales measuring masculinity-femininity and introversion were added later to complete 
the ten basic Clinical Scales of the original MMPI. Hathaway and McKinley (1943) also 
created four scales to assess protocol validity, or the validity of a test-taker’s responses. 
These scales measured non-responding with the Cannot Say (CNS) indicator (i.e., 
number of items left blank or responses of both “true” and “false” to the same item), 
over-reporting with the Infrequency (F) scale, and under-reporting with the Lie (L) scale. 
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Another under-reporting scale, the Correction (K) Scale, was added three years after the 
test was published. The ten basic Clinical Scales and four Validity Scales were the 
standard scales for the original MMPI, and nearly all chronic pain research with the test 
relied on these measures. Descriptions of the standard original MMPI scales are 
presented in Table 1.  
 Most chronic pain research using the MMPI relied upon the derivation of 
subgroups based on patterns of Clinical Scale scores. This strategy was likely 
implemented for two primary, implicit reasons. First, the MMPI’s Clinical Scales 
demonstrate excessively high intercorrelations occurring because of construct and item 
overlap across scales, making investigations of single scale associations problematic. For 
example, Scale 7 (Psychastenia) and Scale 8 (Schizophrenia) demonstrate correlations as 
high as .90 (Tellegen et al., 2003; Wallace & Liljequist, 2005) and share 17 items, despite 
being intended to measure distinct constructs related anxiety psychotic symptoms, 
respectively. The overlap is a result of the empirical keying approach used by Hathaway 
and McKinley (1943) for the derivation of the Clinical Scales. These authors did not take 
into account that choosing items for the Clinical Scales based on their ability to 
differentiate between each clinical group and the non-clinical group introduced in all the 
scales a common factor, demoralization (i.e., a general sense of unhappiness and 
distress). This common demoralization factor was present in all eight clinical groups, 
which were comprised of individuals receiving inpatient psychiatric treatment, but not the 
non-clinical comparison group. Significant construct overlap was introduced in this way. 
Hathaway and McKinley (1943) also allowed for the same item responses to be scored on 
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multiple scales, thus introducing correlated measurement error, which further increased 
intercorrelations between the Clinical Scales. 
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Table 1. Standard Minnesota Multiphasic Personality Inventory (MMPI) Scales 
Validity Scales  
CNS Cannot Say – The number of unanswered items 
L Lie Scale – Tendency to present oneself in an overly-favorable light 
F Infrequency Scale – Tendency to endorse symptoms that are rare and 
infrequent in the general population 
K Defensiveness Scale – Tendency to minimize psychological problems 
Clinical Scales  
1 (Hs) Hypochondriasis – Measures vague somatic complaints 
2 (D) Depression – Measures depressive symptoms 
3 (Hy) Hysteria – Tendency to react with somatic symptoms in response to 
stressful symptoms 
4 (Pd) Psychopathic Deviate – Measures antisocial attitudes and behaviors 
5 (Mf) Masculinity/Femininity – Measures gender roles  
6 (Pa) Paranoia – Measures suspiciousness of others and presence psychotic 
delusions 
7 (Pt) Psychastenia – Measures symptoms of anxiety 
8 (Sc) Schizophrenia – Measures bizarre thoughts and potential psychotic 
symptoms 
9 (Ma) Hypomania – Measures heightened energy level and risk taking 
behavior 
0 (Si) Social Introversion – Tendency to withdraw from social situations 
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The second reason for implementing a subgroup strategy for chronic pain research 
with the MMPI was scale heterogeneity. Clinically significant elevations (i.e., a T-score > 
70T) on the MMPI’s Clinical Scales could occur for a variety of reasons. Elevations on 
Scale 3 (Hysteria), for example, could result from somatic problems, behavioral 
inhibition, and denial of social anxiety (Harris & Lingoes, 1955). For these reasons, 
interpretation of individual scales was difficult, and chronic pain researchers focused on 
the derivation of MMPI subgroups by three main strategies: Mean Profiles, Code Types, 
and Cluster Analyses.  
 
Mean Profiles 
 Early approaches compared mean profiles (i.e., average scores of the Clinical 
Scales scale plotted on a profile sheet) of successfully and unsuccessfully treated chronic 
pain groups. Hanvik (1951) compared MMPI profiles of 30 “organic” back pain cases 
with an identifiable biological cause and 30 “functional” cases of low back pain with no 
identifiable cause. He concluded that a configuration of high scores on scales 
1(Hypochondriasis), 2 (Depression), and 3 (Hysteria) differentiated the functional from 
organic cases. This configuration was known as the “conversion V” profile, because 
elevations on scales 1 and 3 were more pronounced, forming a V-shaped pattern common 
in conversion disorder patients. In a subsequent mean profile comparison, Long (1981) 
investigated differences between 44 chronic low back pain patients who were 
successfully and unsuccessfully treated with surgery. Long found no meaningful 
differences in profiles of surgical successes and failures, attributing his findings to the ill-
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suited use of mean profiles for this purpose. Long (1981) reviewed contemporary 
criticisms of the approach and argued that use of mean profiles assumes a homogenous 
population, but chronic pain patients are a heterogeneous group, with meaningful 
individual differences in scale scores that are masked when average scores are used. He 
presented follow-up analyses comparing the frequencies of various combinations of 
Clinical Scale elevations. Using this approach, he found that all 12 individuals with no 
clinical elevation were surgical successes, whereas all nine individuals with clinical 
elevations only on scales 1 and 3 were surgical failures.  
 
Code Types 
 The problems with using mean Clinical Scale profiles were not unique to chronic 
pain settings. Recognizing these issues in his presidential address to members of the 
American Psychological Association, Meehl (1956) petitioned for the identification of 
combinations of Clinical Scale scores with reliable and unique correlates—a call to action 
that resulted in the development of code type interpretation. A code type was typically 
defined by the two highest clinically elevated scales (two-point code type) but some 
three-point code types were also developed. The 13/31 code type (most elevated scale 
listed first) identified by Long (1981) is one of dozens of two-point code types, and it is 
particularly relevant in chronic pain research.  
 Code types became the most common method of defining subgroups of chronic 
pain patients. McCreary, Turner, and Dawson (1979) categorized 79 chronic low back 
pain patients into five code-type categories: 12/21, 13/31, 123, 23/32, and 18, 38, or 138. 
They found that classifying patients by these code types was more predictive of poor 
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outcome than single scale elevations. However, over half the individuals with a positive 
outcome were misclassified according to the code type method. The authors noted that 
though the code type strategy was preferable to the single-scale method, which was also 
presented, more research was needed.  
 Heaton et al. (1982) categorized 169 chronic pain patients at a multi-disciplinary 
clinic according to seven categorizations: Scale 1 prominently elevated 
(“Hypochondriasis”;  6% of sample), 213/231 code types (“Reactive Depression”; 17%), 
no elevations (“Normal Limits”; 10%), 13/31 code type (“Conversion-V”; 18%), 132/213 
code types (“Neurotic Triad”; 18%), 34/43 code types (“Manipulative Reaction”; 5%), 
and a mostly elevated profile with primary elevations on scales 6, 7, and 8 
(“Psychotic/Borderline”; 9%). Overall, these included approximately 83% of the sample. 
However, none of the subgroupings were significantly associated with extra-test 
measures, including self-reported pain and physician ratings of patient exaggeration. 
Atkinson, Ingram, Kremer, and Saccuzzo (1986) conducted one of the few studies that 
provided empirical support for correlates of MMPI code types in this population. These 
authors assigned psychiatric diagnoses to 52 male chronic pain patients in an inpatient 
pain-treatment program. The authors categorized the patients into three code types: 
312/321 (“Hypochondriasis”; 23% of sample), 213/231 (“Depression”; 27%), and 13/31 
(“Conversion-V”; 33%). They found that rates of major depression diagnoses were 
significantly higher in the depressed group than the other ones. However, no other 
diagnoses were related to subgroup membership.  
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 Overall, although researchers were able to demonstrate that a majority of chronic 
pain patients could be classified according to a fairly parsimonious set of code types, 
these subgroups were primarily descriptive and did not typically show meaningful 
associations with extra-test information. Additionally, the code types were based on 
researchers’ notions of appropriate subgroupings and were not validated with empirical 
analyses.  
 
Cluster Analysis 
 For the reasons just mentioned, empirically-based subgroup identification 
strategies were needed, and a number of researchers began using cluster analysis toward 
this end. This statistical methodology is intended to identify subgroups of individuals 
who are similar to each other but also different from members of other statistically 
derived subgroups (Kaufman & Rousseeuw, 2005). It is a methodology similar to factor 
analysis; however, whereas factor analysis is intended to identify patterns among 
variables, cluster analysis is intended to identify patterns among individual data points. In 
the context of MMPI research, these individual data points were the chronic pain patients 
who were administered the test. A hierarchical clustering procedure has been the most 
widely used subgrouping method in chronic pain research. Following this “bottom-up” 
method, individuals are grouped into a large number of clusters that are progressively 
merged based on MMPI scale score similarities. This process ends when the entire 
sample is a single cluster. The researcher then chooses the optimal number of clusters and 
interprets the findings at that step of the analysis. Given the subjectivity of cluster 
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analysis interpretation, use of a replication sample and investigations of the associations 
between the subgroups and extra-test variables are essential.  
 Bradley and colleagues developed a set of MMPI cluster analytic solutions over 
the course of the late 1970’s through early 1980’s (Bradley, Prokop, Margolis, & Gentry, 
1978; Bradley & van der Heide, 1984). They initially used a hierarchical clustering 
strategy in three samples of chronic low back pain patients, which they ran separately by 
gender. They found four subgroups that replicated across the female samples. The first 
subgroup had elevations on scales 1, 2, and 3 (“Neurotic Triad”; 23% of sample). The 
second subgroup was a within-normal-limits profile averaging no elevations on the 
Clinical Scales (39%). The third group had elevated scores on scales 1, 2, 3, 4, and 8 
(“Generally Elevated”; 13%). The final group was characterized by a conversion-V 
pattern (24%). The male samples also demonstrated the neurotic triad (44% of sample) 
and within-normal-limits profiles (46%), as well as the generally elevated group (10%). 
However, the conversion-V group was not present among the males. These solutions 
would be replicated by other researchers, who examined associations between the 
subgroups and extra-test information.  
 Armentrout, Moore, Parker, Hewett, and Feltz (1982) replicated Bradley and 
colleagues’ cluster analytic solutions in a sample of male chronic pain patients and 
examined external correlates of these subgroups. No significant differences occurred 
between groups on age, education, income, IQ, assertiveness, pain type, or pain duration. 
However, the authors found that the generally-elevated group reported higher pain 
severity and disability than the neurotic-triad group and within-normal-limits group. 
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Leavitt and Garron (1982) sampled 150 hospitalized low back pain patients. They found 
no significant differences between within-normal-limits, conversion-V, and generally-
elevated groups on demographics, surgical history, or pain duration. The within-normal-
limits group reported significantly less pain than the other groups, and the generally-
elevated group reported the most intense pain experience. McGill, Lawlis, Selby, 
Mooney, and McCoy (1983) selected 46 male and 46 female chronic low back pain 
patients and replicated Bradley and colleagues (1978) four cluster solution among the 
females and three cluster solution among the males. The neurotic-triad group had 
significantly more hospitalizations and surgeries than the other groups. The within-
normal-limits group reported the lowest pain severity and disability, as well as 
significantly less hospitalizations and surgeries. The generally-elevated group reported 
the most pain at intake and discharge. Finally, the conversion-V group had the longest 
duration of pain.  However, McGill et al. (1983) found no differences between groups on 
a variety of outcome measures, including drug use, functioning, and ratings of physical 
improvement.  
 After researchers generally replicated the cluster solutions first indicated by 
Bradley and colleagues (1978) and provided extra-test correlations demonstrating the 
characteristics of these subgroups, cluster analysis research turned toward outcome 
prediction. Unfortunately, multiple studies failed to support an association between the 
subgroups and outcome. McCreary (1985) sampled 401 low back pain patients and found 
four clusters for both sexes: generally-elevated, neurotic-triad, unelevated neurotic-triad, 
and an unelevated profile with highest scores on scales 1, 3, 4, and 9. The females also 
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had a conversion-V cluster. The general-elevation group and conversion-V group had 
worse pain outcomes than the two unelevated groups. However, the findings did not 
replicate across genders, and the subgroups were better predictors of outcome among 
males. Moore, Armentrout, Parker, and Kivlahan (1986) assigned 57 male chronic pain 
inpatients to three clusters identified by Bradley et al. (1978): within-normal-limits, 
generally-elevated, and neurotic-triad. The subgroups did not have differential outcome, 
despite the inclusion of a variety of self-report outcome measures. Guck, Meilman, 
Skultety, and Poloni (1988) examined 635 chronic pain inpatients and replicated the 
clusters identified by Bradley et al. (1978).  They found no meaningful associations with 
long-term treatment outcomes approximately two years after treatment.  
 Although use of cluster analysis with the MMPI was an improvement compared 
to code-types because the subgroups were empirically based, well-replicated, and 
associated with concurrent extra-test information, their use in the prediction of treatment 
outcome was not supported by the research. The MMPI’s lack of utility in this context 
was likely due in part to the previously mentioned structural problems that necessitated 
the use of subgroups instead of individual scales. Though the majority of chronic pain 
patients could be classified into one of three to five subgroups, meaningful individual 
differences within each group were masked. The development and introduction of the 
MMPI-2 (Butcher, Dahlstrom, Graham, Tellegen, & Kaemmer, 1989) in the mid to late 
1980’s was an opportunity to address these structural problems.  
 
The MMPI-2 and Chronic Pain 
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 The authors of the MMPI-2 had two primary and potentially incompatible goals: 
1) improve the test; and 2) maintain continuity with the original MMPI (Ben-Porath, 
2012). The test was improved by updating item vocabulary, adding new items, and 
collecting an updated standardization sample. The authors chose to make minimal 
changes to the Clinical and Validity Scales in order to preserve continuity with the 
original MMPI, which had developed a substantial research base since its publication in 
the 1940’s. However, they added new scales that they believed would aid in the 
interpretation of the Clinical Scales.  
 In an effort to maintain continuity while also improving the test, a set of Content 
Scales that included original MMPI items and newly added ones was developed (Butcher, 
Graham, Williams, & Ben-Porath, 1990). The Content Scales were developed using a 
rational-consensus approach, with the test authors assigning items to scales. Their 
internal consistency and intercorrelations were later refined until they achieved 
acceptable levels. This process yielded 15 scales: Anxiety (ANX), Fears (FRS), 
Obsessiveness (OBS), Depression (DEP), Health Concerns (HEA), Bizarre Mentation 
(BIZ), Anger (ANG), Cynicism (CYN), Antisocial Practices (ASP), Type-A Behavior 
(TPA), Low Self-esteem (LSE), Social Discomfort (SOD), Family Problems (FAM), 
Work Interference (WRK), and Negative Treatment Indicators (TRT). In contrast to the 
Clinical Scales, the Content Scales had significantly less construct overlap and were more 
homogeneous measures.  
 Despite the introduction of the Content Scales, studies of the MMPI-2 among 
chronic pain patients continued to focus primarily on Clinical Scale code type and cluster 
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comparability with the MMPI. Keller and Butcher (1991) conducted the first 
comprehensive study of chronic pain and the MMPI-2 in a sample of 502 patients 
administered a booklet that allowed for scoring of both versions of the test. They found 
that a majority of patients had identical code types across the MMPI and MMPI-2 norms 
and replicated the cluster analysis subgroups previously found in MMPI research. 
However, the authors noted that “there were relatively few specific correlates of any of 
these subgroups considering the large amount of patient data that had been collected” 
(Keller & Butcher, 1991, p. 127). They suggested that future research “concentrate on 
developing clearly defined, replicable code type rules” (p. 128).  
 Research continued to focus on code type and cluster replicability. Riley, 
Robinson, Geisser, and Wittmer (1993) investigated a sample of 201 low back pain 
patients administered the MMPI-2 and replicated the four cluster solution typically 
derived for the MMPI: neurotic-triad, conversion-V, within-normal-limits, and generally-
elevated clusters. In a follow up study, Riley, Robinson, Geisser, Wittmer, and Smith 
(1995) replicated this solution in a subsample of chronic pain patients undergoing back 
surgery. They found that some subgroups were predictive of outcome. In particular, the 
within-normal-limits and neurotic-triad subgroups had significantly more satisfaction 
with postsurgical improvement. However, the groups did not significantly differ on 
objective measures of outcome, including physical activity and work status.  
 
The MMPI and MMPI-2: “Security Blanket or Sound Investment?”  
 Though traditionally the most widely administered psychological test to chronic 
pain patients (Piotrowski, 1998; Piotrowski & Lubin, 1990), the MMPI and MMPI-2 
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began falling out of favor in chronic pain settings in the mid to late-1990’s. During this 
time, a series of articles debating the utility of the tests was published in Pain Forum. 
Main and Spanswick (1995) began the debate with their article entitled “Personality 
assessment and the Minnesota Multiphasic Personality Inventory: 50 years on: Do we 
still need our security blanket?” The authors criticized the test for its psychometric 
shortcomings, writing, “Its inherent structural weaknesses undermine its clinical validity, 
even when it does provide additional clinical information” (p. 92). They called for 
chronic pain outcome studies using advanced quantitative analyses such as structural 
equation modeling and more focused cognitive and behavioral measures consistent with 
the previously mentioned bio-psycho-social model of pain, “which reflect the world of 
pain rather than promulgate the sort of psychoarcheology represented by the MMPI and 
MMPI-2” (p. 95).  
 Bradley (1995) countered these claims in the next article of the series. He 
reviewed a series of research studies indicating that individuals can be reliably 
categorized into MMPI scale score subgroups, which demonstrate concurrent associations 
with factors that may predict outcome, such as pain intensity, medication use, disability, 
and work status. He also critiqued Main and Spanswick (1995) for “selective abstraction” 
in their conclusion that the MMPI is not correlated with outcomes among chronic pain 
patients. However, Bradley (1995) only referenced three studies that supported this 
association, the most compelling of which was the previously described McCreary (1985) 
investigation. Finally, Bradley (1995) agreed that integrating psychological testing with 
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the bio-psycho-social model of pain was indicated, but contended that the MMPI and 
MMPI-2 could potentially be used for this purpose.  
 In contrast to the two positions just mentioned, Keefe, Lefebvre, and Beaupre 
(1995) presented a more balanced critique of the MMPI and MMPI-2 in chronic pain 
settings. These authors indicated that “the fault with the MMPI may lie, not so much in 
the instrument, but in the way it came to be used in clinical practice” (p. 101). They 
argued that it is most appropriately used as a multidimensional measure of personality, 
not as the sole indicator for making dichotomous judgments, such as distinguishing 
between organic and functional pain (e.g., Hanvik, 1951). The authors agreed that more 
sophisticated quantitative analyses (e.g., structural equation modeling and regression tree 
analysis) may improve prediction of treatment outcomes, which they also agreed needed 
more research. However, Keefe et al. (1995) also notes a number of strengths of the 
MMPI and MMPI-2, including the standardized scoring of the test, ability to identify 
significant psychopathology, and the availability of Clinical Scale subscales (i.e., Harris-
Lingoes subscales; Harris & Lingoes, 1955).  
 Keefe et al. (1995) summarized the results of two studies that demonstrated the 
utility of these subscales. Bigos et al. (1992) conducted a longitudinal study at the Boeing 
Aircraft Company. The authors followed over 3000 employees, a 279-person subset of 
which reported back pain after the study was initiated. They found that Clinical Scale 3 
(Hysteria) was associated with the development of back pain approximately four years 
after baseline. In a follow up study (Fordyce, Bigos, Batti'e, & Fisher, 1992), the authors 
refined their approach, attempting to identify which constructs measured by the 
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heterogeneous Clinical Scale 3 were driving the association. They found that three of the 
five Harris-Lingoes subscales for Scale 3 were associated with subsequent back injury 
reporting: Lassitude and Malaise, Denial of Social Anxiety, and Need for Affection. The 
subscales Somatic Complaints and Inhibition of Aggression, however, were not 
associated with subsequent back injury reporting. Keefe et al. (1995) encouraged authors 
to further emphasize the Harris Lingoes subscales in future research, but cautioned that 
the reliability for some of the subscales was inadequate.  
 In the next article of the series, Turk and Fernandez (1995) reiterated criticisms of 
the functional limitations of the MMPI and MMPI-2 among chronic pain patients as 
described by Main and Spanswick (1995). They further criticized use of the test with 
chronic pain patients because its Clinical Scales were based upon outdated models of 
psychopathology, which rendered identification of personality and psychological issues 
among chronic pain patients problematic. Helmes and Reddon (1993) had advanced a 
similar position on the MMPI and MMPI-2 in a wide-spanning criticism of the 
instruments, noting that the Kraepelinian typology that was used in the development of 
MMPI’s Clinical Scales was an antiquated model of psychopathology. They wrote that 
“the strong emphasis on continuity by the [MMPI] Restandardization Committee forwent 
the opportunity to renew the nature of the MMPI and resulted in such obsolete remnants 
being retained” (p. 456).  
 Overall, most of the authors in the series agreed that though the MMPI-2 showed 
some promise for use with chronic pain patients, significant problems with the test’s 
Clinical Scales (which were nearly identical to the MMPI’s Clinical Scales) remained. 
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Those who were most critical of the MMPI-2 advocated for substantially decreased use 
of the test for this purpose, whereas others supported alternative interpretation strategies, 
such as use of subgroups (i.e., via cluster analysis and code types) or other scales. The 
former strategy, however, had generally failed to demonstrate meaningful correlations 
with extra-test criteria. Both sides agreed, however, that more research on the MMPI-2 
was needed.  
 
New Areas of Research  
 An update of the MMPI-2 manual, published in 2001(Butcher et al., 2001), added 
new measures to the standard scoring protocol, including the Personality-
Psychopathology-5 Scales (PSY-5; Harkness, McNulty, & Ben-Porath, 1995) and 
Content Component Scales (Ben-Porath & Sherwood, 1993). The PSY-5 scales were 
developed to measure the following five broad personality-pathology domains: 
Aggressiveness (AGGR), Psychoticism (PSYC), Disconstraint (DISC), Negative 
Emotionality/Neuroticism (NEGE), and Introversion/Low Positive Emotionality (INTR). 
The Content Component Scales were subscales of the Content Scales that were designed 
to clarify their interpretation, similar to how the Harris-Lingoes subscales are used in 
conjunction with the Clinical Scales. These new sets of scales, along with the 
underutilized Content Scales, afforded new opportunities for research with chronic pain 
patients that could address the challenges concerning the utility of the MMPI-2 in this 
setting.  
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 Content and Content Component Scales. Some studies provided preliminary 
evidence for the utility of the Content and Content Component Scales among chronic 
pain patients. Clark (1996) administered the MMPI-2 along with collateral pain intensity 
and emotional distress measures to 113 male chronic pain patients. Focusing solely on the 
Negative Treatment Indicators (TRT) Content Scale and Content Component Scales, he 
found that scores on TRT were negatively associated with self-reported physical 
capabilities and emotional distress at discharge after controlling for intake scores and 
demographics. Among the Content Component Scales, Low Motivation (TRT1) was 
significantly associated with decreased physical capabilities and increased pain intensity 
at discharge, but the other TRT Content Component Scale, Inability to Disclose (TRT2), 
was not associated with outcome.  
 Vendrig, Derksen, and de Mey (1999) sampled 120 consecutive spinal pain 
patients at a multi-disciplinary pain clinic. They administered the MMPI-2, as well as 
pain disability, intensity, and functioning measures. The authors examined Clinical 
Scales 2, 3, and 7 in addition to Content Scales Depression (DEP), Health Concerns 
(HEA), Anxiety (ANX), and Obsessiveness (OBS). They generally found that Clinical 
Scale scores were negatively associated with improvement in pain disability and 
intensity, and with the exception of OBS the Content Scales lacked significant 
associations with outcome.  
 Strassberg and Russell (2000) directly evaluated the incremental validity of select 
Content Scales (DEP, ANX, Anger [ANG], and Low Self-Esteem [LSE]) in reference to 
similar Clinical Scales (2, 4, 7) in a sample of 341 chronic pain patients. They found that 
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all Content Scales added incrementally to the Clinical Scales in the prediction of 
concurrent self-reported and therapist rated depression, anxiety, anger, and self-esteem, 
with the exception of LSE failing to add incrementally to scale 2 in the prediction of 
therapist rated self-esteem. The Content Scales also generally demonstrated similar to 
improved zero-order correlations with these variables.   
 
 PSY-5 Scales. Vendrig, Derksen, and de Mey (2000) provide the only 
investigation of the association between the PSY-5 scales and chronic pain outcomes. 
They sampled 120 consecutive chronic pain patients in a multi-modal treatment program 
who were administered the MMPI-2 and pain intensity and disability outcome measures, 
as well as satisfaction with treatment and emotional change patient ratings. They found 
that INTR was significantly associated with satisfaction with treatment and emotional 
change at discharge after controlling for intake scores and demographics. Additionally, 
AGGR was predictive of ongoing post-treatment use of pain medications.  
 Overall, though research on the PSY-5 as well as the Content and Content 
Component Scales was generally promising, they were under-researched and under-
utilized with chronic pain patients. Researchers continued to focus on the Clinical Scales 
of the MMPI-2, despite serious psychometric concerns (Vendrig, 2000).  
 
 Restructured Clinical Scales. The MMPI-2 Restructured Clinical (RC) Scales 
were added to the standard MMPI-2 scoring protocol in 2003 and represented the most 
significant step towards modernizing the instrument (Tellegen et al., 2003). The primary 
goal of the RC Scales project was to address the psychometric problems of the Clinical 
  
23 
 
Scales by substantially reducing the scale overlap and heterogeneity that complicated 
their interpretation and use in research, while still measuring the major distinctive core 
constructs assessed by each scale. To this end, development of the RC Scales proceeded 
in four steps.  
 The first step was to identify and measure the previously mentioned 
demoralization factor that was present in all the Clinical Scales because of the test 
construction approach used by Hathaway and McKinley (1943). This common factor led 
to significant overlap across the scales, but was most prominent in Clinical Scales 2 and 
7. A factor analysis of these two scales yielded 23 items common to both scales that 
measured a distinct demoralization construct. The second step was to identify the core 
components of each Clinical Scale after factoring out demoralization. The RC Scales’ 
internal consistency and mutual distinctiveness was optimized in steps three and four 
using correlational analyses. The product of these analyses were eight non-overlapping 
scales that measured the major distinctive core constructs of scales 1, 2, 3, 4, 6, 7, 8, and 
9, along with an additional RC Scale measuring demoralization. The RC Scales are 
consistent with contemporary models of psychopathology (see Table 2 for a comparison 
between the RC and Clinical Scales). Since their inception, the RC Scales have been the 
subject of over 100 research studies and have substantial external validity information to 
support their use (Ben-Porath, 2012). 
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Table 2. Minnesota Multiphasic Personality Inventory-2 Restructured Clinical Scales 
versus Standard Clinical Scales 
Restructured Clinical Scales Clinical Scales 
RCd (Demoralization) N/A 
RC1 (Somatic Complaints) 1 (Hypochondriasis)  
RC2 (Low Positive Emotions) 2 (Depression)  
RC3 (Cynicism) 3 (Hysteria) 
RC4 (Antisocial Behavior) 4 (Psychopathic Deviate) 
N/A 5 (Masculinity/Femininity)  
RC6 (Persecutory Ideation) 6 (Paranoia) 
RC7 (Dysfunctional Negative Emotions) 7 (Psychastenia) 
RC8 (Aberrant Experiences) 8 (Schizophrenia)  
RC9 (Hypomanic Activation) 9 (Hypomania) 
N/A 0 (Social Introversion) 
Note. N/A (Not Applicable) 
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 The RC Scales were designed to address the previously mentioned criticisms of 
the Clinical Scales, which were negatively evaluated for use with chronic pain patients 
because of their psychometric problems and reliance upon an outdated model of 
psychopathology. Indeed, McCord and Drerup (2011) demonstrated the improved 
interpretive utility of the RC Scales in comparison to the Clinical Scales in a chronic pain 
sample. These authors categorized 316 chronic pain patients into depressed and non-
depressed diagnostic groups. The depression group included individuals diagnosed with 
major depression, dysthymia, and adjustment disorder, whereas the non-depressed group 
was not diagnosed with any form of mood disturbance. They compared mean scores on 
the Clinical and RC Scales across the two groups. In the non-depressed group, mean 
Clinical Scale elevations (i.e., scores > 65T) were found on scales 1 (Hypochondriasis), 2 
(Depression), 3 (Hysteria), and 8 (Schizophrenia), whereas only RC1 (Somatic 
Complaints) produced a mean RC Scale elevation. In the depressed group, mean clinical 
elevations were observed for the following Clinical Scales: 1 (Hypochondriasis), 2 
(Depression), 3 (Hysteria), 4 (Psychopathic Deviate), 6 (Paranoia), 7 (Psychastenia), and 
8 (Schizophrenia). The pattern of elevations was consistent with the neurotic-triad cluster 
and code type typically found in Clinical Scale research in this setting, with prominent 
elevations on scales 1, 2, and 3. In stark contrast to the Clinical Scale findings, mean RC 
scale elevations were observed in the depressed group for only RCd (Demoralization), 
RC1 (Somatic Complaints), and RC2 (Low Positive Emotions), demonstrating 
substantially improved discriminant validity. McCord and Drerup (2011) summarize the 
implications of the findings from the depressed group: 
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 “The clinician relying on the Clinical Scales would see clinical-range elevations 
on all scales except Scale 9, with extreme elevations on Scales 1, 2, and 3 and troubling 
elevations on 7 and 8 as well. In contrast, the RC Scales indicate three things: (a) a 
significant level of demoralization; (b) significant somatic complaints; and (c) 
depression. The latter set of data is far more consistent with the clinical diagnoses in the 
patient charts” (p. 145).  
 Despite the substantial psychometric and interpretive improvements compared to 
the Clinical Scales, no other study has investigated use of the RC Scales among chronic 
pain patients undergoing conventional conservative treatments. Although a body of 
research has been developed on use of these measures in the prediction of spinal surgery 
outcome (Block, Ben-Porath, & Marek, 2013), research on the MMPI instruments among 
chronic pain patients has substantially diminished. The controversy concerning the 
Clinical Scales that began in the mid-1990’s and the focus on continuity in MMPI and 
MMPI-2 research despite generally equivocal results seems to have swayed researchers 
and clinicians toward shorter and more symptom-focused measures. It is perhaps for 
these reasons that the utility of the RC Scales and their new parent measure, the MMPI-2-
Restructured Form (MMPI-2-RF; Ben-Porath & Tellegen, 2008/2011), have yet to be 
explored among chronic pain patients.  
 
The Current Study 
 The MMPI-2-RF shows particular promise for reviving research on the MMPI in 
chronic pain settings. The test is anchored by the RC Scales, which are improved versions 
of the Clinical Scales typically relied upon in previous chronic pain research, and the test 
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authors used similar development strategies for two new scale sets: the Higher-Order and 
Specific Problems Scales. Additionally, revised and improved versions of the MMPI-2 
PSY-5 have been incorporated into the test. The result is a 338-item broadband 
personality-psychopathology measure with 42 substantive scales measuring five broad 
domains: Somatic/Cognitive Dysfunction, Emotional Dysfunction, Thought Dysfunction, 
Behavioral Dysfunction, and Interpersonal Functioning (see Table 3 for descriptions of 
all MMPI-2-RF scales). 
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Table 3. Minnesota Multiphasic Personality Inventory-2-Restructured Form Scales 
Validity Scales 
 Inconsistent Responding 
VRIN-r Variable Response Inconsistency – Random Responding 
 TRIN-r True Response Inconsistency – Fixed Responding 
  
 Overreporting 
F-r Infrequent Responses – Responses infrequent in the general 
population 
Fp-r Infrequent Psychopathology Responses – Responses infrequent in 
psychiatric populations 
FS Infrequent Somatic Responses – Somatic complaints infrequent in 
medical patient populations 
FBS-r Symptom Validity – Somatic and cognitive complaints associated 
at high levels with overreporting 
RBS Response Bias Scale – Exaggerated memory complaints 
 
Underreporting 
L-r Uncommon Virtues – Rarely claimed moral attributes or activities 
K-r Adjustment Validity – Avowals of good psychological adjustment 
associated at high levels with underreporting 
 
Higher-Order (H-O) Scales 
EID Emotional/Internalizing Dysfunction – Problems associated with 
mood and affect 
THD Thought Dysfunction – Problems associated with disordered 
thinking 
BXD Behavioral/Externalizing Dysfunction – Problems associated with 
under-controlled behavior  
 
Restructured Clinical (RC) Scales 
RCd Demoralization – General unhappiness and dissatisfaction 
RC1 Somatic Complaints – Diffuse physical health complaints 
RC2 Low Positive Emotions – Lack of positive emotional 
responsiveness 
RC3 Cynicism – Non-self-referential beliefs expressing distrust and a 
generally low opinion of others 
RC4 Antisocial Behavior – Rule breaking and irresponsible behavior 
RC6 Ideas of Persecution – Self-referential beliefs that others pose a 
threat 
RC7 Dysfunctional Negative Emotions – Maladaptive anxiety, anger, 
irritability 
RC8 Aberrant Experiences – Unusual perceptions or thoughts 
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RC9 Hypomanic Activation – Over-activation, aggression, impulsivity, 
and grandiosity 
 
Specific Problem (SP) Scales 
  
 Somatic/Cognitive Scales 
  MLS Malaise – Overall sense of physical debilitation, poor health 
GIC Gastrointestinal Complaints – Nausea, recurring upset stomach, 
and poor appetite 
HPC Head Pain Complaints – Head and neck pain 
NUC Neurological Complaints – Dizziness, weakness, paralysis, loss of 
balance, etc. 
COG Cognitive Complaints – Memory problems, difficulties 
concentrating 
 
Internalizing Scales 
SUI Suicidal/Death Ideation – Direct reports of suicidal ideation and 
recent suicide attempts 
HLP Helplessness/Hopelessness – Belief that goals cannot be reached or 
problems solved 
SFD Self-Doubt – Lack of confidence, feelings of uselessness 
NFC Inefficacy – Belief that one is indecisive and inefficacious 
STW Stress/Worry – Preoccupation with disappointments, difficulty 
with time pressure 
AXY Anxiety – Pervasive anxiety, frights, frequent nightmares 
ANP Anger Proneness – Becoming easily angered, impatient with others 
BRF Behavior-Restricting Fears – Fears that significantly inhibit normal 
activities 
MSF Multiple Specific Fears – Fears of blood, fire, thunder, etc. 
 
Externalizing Scales 
JCP Juvenile Conduct Problems – Difficulties at school and at home, 
stealing 
SUB Substance Abuse – Current and past misuse of alcohol and drugs 
AGG Aggression – Physically aggressive, violent behavior 
ACT Activation – Heightened excitation and energy level 
 
Interpersonal Scales 
FML Family Problems – Conflictual family relationships   
IPP Interpersonal Passivity – Being unassertive and submissive 
SAV Social Avoidance – Avoiding or not enjoying social events 
SHY Shyness – Bashful, prone to feel inhibited and anxious around 
others 
DSF Disaffiliativeness – Disliking people and being around them 
  
30 
 
 
Interest Scales 
 AES  Aesthetic-Literary Interests – Literature, music, the theater 
 MEC  Mechanical-Physical Interests – Fixing and building things, the 
outdoors, sports 
 
Personality Psychopathology Five (PSY-5) Scales 
 AGGR-r Aggressiveness-Revised – Instrumental, goal directed aggression 
 PSYC-r Psychoticism-Revised – Disconnection from reality 
 DISC-r Disconstraint-Revised – Under-controlled behavior 
 NEGE-r Negative Emotionality/Neuroticism-Revised – Anxiety, insecurity, 
worry, and fear 
 INTR-r Introversion/Low Positive Emotionality-Revised – Social 
disengagement and anhedonia 
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 The three Higher-Order Scales—Emotional/Internalizing Dysfunction (EID), 
Thought Dysfunction (THD), and Behavioral/Externalizing Dysfunction (BXD)—were 
developed based on factor analyses of the RC Scales that consistently identified three 
superordinate factors marked by RCd, RC2, and RC7; RC6 and RC8; and RC4 and RC9, 
respectively. The Higher-Order Scales are consistent with the three most common two-
point code types in the MMPI and MMPI-2 literature (27/72, 68/86, and 49/94, 
respectively). However, whereas code types are categorical and mutually exclusive, the 
Higher-Order Scales are dimensional and enable identification of dysfunction in all three 
domains simultaneously. Additionally, these scales are consistent with contemporary 
higher-order models of the structure of psychopathology (Sellbom, Ben-Porath, & Bagby, 
2008).  
 Construction of the RC Scales also yielded the identification of several more 
narrowly focused constructs. To assess these, the authors developed 23 Specific Problems 
Scales that measure RC Scale subdomains or other narrow constructs that are related to 
but distinct from those measured by the RC Scales. The Specific Problems Scales are 
organized into five domains: 1) Somatic/Cognitive Scales, 2) Internalizing Scales, 3) 
Externalizing Scales, 4) Interpersonal Scales, and 5) Interest Scales. These scales focus 
interpretations of the RC Scales in a manner suggested by critics of the Clinical Scales 
(Keefe et al., 1995).  
 Rounding out the hierarchy of the substantive scales are revised and improved 
versions of the PSY-5 scales. These scales were developed beginning with the PSY-5 
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items that remained in the MMPI-2-RF item pool with MMPI-2-RF items added based on 
further analyses designed to improve the discriminant validity of these measures. As a 
result, the MMPI-2-RF PSY-5 scales demonstrate lower intercorrelations and comparable 
to improved external validity in comparison to the original PSY-5 scales (Harkness & 
McNulty, 2007; Harkness et al., 2013).  
 In addition to these psychometric improvements, because the MMPI-2-RF is 
consistent with current models of psychopathology, it is likely also compatible with the 
bio-psycho-social model of pain discussed earlier. This is in contrast to the MMPI and 
MMPI-2, whose Clinical Scales were based on the outdated Kraepelinian typology. The 
psychological component of the bio-psycho-social model is primarily influenced by 
mood and cognitions, and dysfunction in both of these areas are measured by the MMPI-
2-RF’s Internalizing and Thought Dysfunction domains, respectively.  
 
Purpose 
 The purpose of the current study was to evaluate the MMPI-2-RF for use in 
assessing chronic low back pain patients entering multidisciplinary treatment. To this 
end, I sought to address the following research questions: 
 
 
1) Do the MMPI-2-RF substantive scale scores demonstrate adequate reliability 
among low back pain patients? 
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2) Do the MMPI-2-RF substantive scale scores show evidence for concurrent 
validity with pain and mental health variables in a low back pain patient 
sample? 
 
3) Do the MMPI-2-RF substantive scale scores predict pain-related outcome at 
discharge in a low back pain patient sample? 
 
4) Extending the findings of McCord and Drerup (2011), do the RC Scales 
demonstrate improved interpretive utility compared to the MMPI-2’s Clinical 
Scales among groups of low back pain patients presenting with the following: 
depression, substance use disorder, and no mental disorder? 
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METHOD 
 
Participants 
 Participants included an archival sample of 875 non-consecutive chronic pain 
patients (346 males, 529 females) that completed the MMPI-2 and presented with lower 
back pain to a short-term multidisciplinary pain treatment program in Northeast Ohio. 
Approximately 85% of the sample completed the program. Patients who completed the 
program participated for an average of 21.1 days (SD = 10.0). Participants were excluded 
from the analyses if they produced invalid MMPI-2-RF profiles according to the test 
authors’ published guidelines, which included: Cannot say, CNS >  Raw Score 18; 
Variable Response Inconsistency, VRIN-r > 80; True Response Inconsistency, TRIN-r > 
80; Infrequent Responding, F-r > 100; and Infrequent Psychopathology Responses, Fp-r 
> 120 (Ben-Porath & Tellegen, 2008/2011). The final sample included 811 patients (318 
males, 493 females) after exclusion. The majority of the sample was married (61.0%) and 
other martial statuses included divorced (17.9%), never married (15.9%), separated 
(3.1%), and widowed (2.1%). The average age was 46.7 (SD = 12.6) and the average 
years of education was 13.3 (SD = 3.8). Excluded individuals had significantly less 
education than the final sample, t(816) = 2.851, p = .004, Cohen’s d = .41. No other 
significant differences were observed (p’s > .150).  
 
Measures
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MMPI-2-RF. As previously described in detail, the MMPI-2-RF (Ben-Porath & 
Tellegen, 2008/2011) is a 338 item self-report broadband measure of psychopathology. It 
has nine Validity Scales designed to assess the test-taking approach and 42 Substantive 
Scales that measure the following domains: Emotional Dysfunction, Thought 
Dysfunction, Behavioral Dysfunction, Somatic/Cognitive Complaints, and Interpersonal 
Functioning.  
 
Pain Disability Index. The Pain Disability Index (PDI; Tait, Chibnall, & Krause, 
1990)  is a 7-item self-report measure that assesses pain related disability in the following 
domains: Family/Home Responsibilities, Recreation, Social Activity, Occupation, Sexual 
Behavior, Self-Care, and Life-Support Activity. It has demonstrated adequate test-retest 
reliability and internal consistency among chronic pain patients (Tait et al., 1990). In the 
current sample, the PDI items yielded a total score internal consistency of .83.  
 
Physical Ability Tests. These tests included the number of stairs climbed in one 
minute, functional reach in inches, distance walked in six minutes, and time to rise from 
seated position. 
 
Depression, Anxiety, Stress Scales. The Depression, Anxiety, Stress Scales 
(DASS; Lovibond & Lovibond, 1996) is a 42-item self-report measure of mood 
problems. It has three scales measuring depression, anxiety, and generalized distress. It 
has demonstrated adequate internal consistency reliability in a variety of settings 
(Lovibond & Lovibond, 1996). 
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University of Alabama Pain Behavior Rating Scales. The University of 
Alabama (UAB) Pain Behavior Scales (Scott, Nepomuceno, Riles, & Suer, 1982) is a 10 
item clinician rated measure that assesses the number of physical pain behaviors a patient 
displays. Specifically, it assesses the following behaviors: Verbal Complaints, Non-
Verbal Complaints, Down-Time, Facial Grimaces, Standing Posture, Mobility, Body 
Language, Use of Visible Support Equipment, Stationary Movement, and Medication 
Usage.  
 
Medical Record Information. A number of variables were extracted from the 
patient’s medical record.  These included patient demographics, diagnoses, substance use 
history, medications, and pain intensity ratings.   
 
Procedure 
 All chronic pain patients received a psychological evaluation at intake into the 
short-term chronic pain rehabilitation program. These psychological evaluations included 
the MMPI-2 and a variety of self-report measures. Evaluation dates ranged from 1999 
through 2008.  In the current study, MMPI-2 items were used to calculate MMPI-2-RF 
scale scores, which is possible because all 338 MMPI-2-RF items are included in the 
MMPI-2 booklet. Past research has demonstrated the relative comparability of MMP-2-
RF scale scores generated from both booklets (Tellegen & Ben-Porath, 2008/2011; Van 
der Heijden, Egger, & Derksen, 2010). Data were collected from 1999 to 2008.  
 
Analysis Plan  
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 Research Question 1. The first research question was: Do the MMPI-2-RF’s 
substantive scales demonstrate adequate reliability among low back pain patients? To 
this end, mean inter-item correlations, standard errors of measurement, and internal 
consistency are presented for all substantive scales along with normative sample 
reliability estimates. It was hypothesized that reliability coefficients in the chronic pain 
sample would approximate those presented for the normative sample. Specifically, I 
hypothesized that all substantive scales will have internal consistency reliabilities that are 
no less than .10 lower than the normative sample, mean inter-item correlations that are no 
less than .05 lower than the normative sample, and standard errors of measurement that 
are within one T-score point of the normative sample. These criteria have been used in 
past research demonstrating the comparability of MMPI-2-RF scale score reliability 
estimates in a medical setting with normative sample estimates (Tarescavage, Wygant, 
Boutacoff, & Ben-Porath, 2013). Overall, the Higher-Order, RC, and PSY-5 Scales were 
hypothesized to demonstrate relatively stronger reliability due to their greater length 
compared to the Specific Problem Scales.  
 
 Research Question 2. The second research question was: Do the MMPI-2-RF’s 
substantive scales have evidence for concurrent validity with pain and mental health 
variables in a low back pain patient sample? To address this question, zero-order 
correlations are presented between the MMPI-2-RF substantive scales and variables 
assessed at intake (see Table 4 for list of criteria). It was hypothesized that MMPI-2-RF 
scales from the Internalizing Dysfunction domain would demonstrate statistically 
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significant small to moderate associations with the DASS, PDI, and mental health history 
variables. These MMPI-2-RF scales measure constructs associated with mood and 
anxiety disorders that likely interact with physical pain to exacerbate physical disability 
(Gatchel, 2004). Similarly, scales from the Thought Dysfunction domain were 
hypothesized to be correlated with the PDI because cognitive factors are also associated 
with pain disability. I also hypothesized that these MMPI-2-RF scales would be 
associated with antipsychotic medication use given that they measure constructs 
associated with psychotic disorders, and I expected that these scales would be correlated 
with Post-Traumatic Stress Disorder (PTSD) diagnosis based on findings in past research 
demonstrating that individuals with PTSD score higher on these scales due to re-
experiencing symptoms (Arbisi, Polusny, Erbes, Thuras, & Reddy, 2011). Scores from 
the Externalizing domain were hypothesized to demonstrate small to moderate 
associations with current smoking and narcotic medication use, as this domain’s scales 
measure acting out behaviors such as substance abuse. Somatic/Cognitive Dysfunction 
scale scores, which measure various physical complaints, were expected to have small to 
moderate correlate with hours resting per day, number of medications, narcotic pain 
medication use, duration of pain, pain intensity, depressive diagnosis, the PDI, physical 
ability tests, and the UAB Pain Behavior Scales. Finally, the Interpersonal Functioning 
Scales were expected to demonstrate small to moderate associations with the PDI 
Family/Home, Recreation, Socialization, and Sexual disability scales, which measure 
pain disability particular to interpersonal situations.  
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Table 4. Research Question 2: External Criteria for Zero-Order Correlations 
Medical Record Criteria 
 Duration of pain 
 Current Smoker 
 Pain Intensity Rating 
 Narcotic Pain Medication Use 
 Number of Medications 
 Antidepressant Medication Use 
 Antipsychotic Medication Use 
 Years since Last Employment 
 Appealing Disability Claim 
 Hours Resting per Day   
DSM-IV Diagnoses  
 Depression 
 Anxiety 
 Substance Use 
 Somatization Disorder 
 Bipolar Disorder 
 Post-Traumatic Stress Disorder 
Self-Report Instruments 
 Pain Disability Index (PDI) 
  Total Score 
Family/Home 
  Recreation 
  Socialization 
  Occupation 
  Sexual 
  Self-Care 
  Life Support 
 Depression Anxiety Stress Scales (DASS) 
  Depression 
  Anxiety 
  Stress 
Physical Ability Tests 
 Number of Stairs Climbed in One Minute 
 Functional Reach in Inches 
 Distance Walked in Six Minutes 
 Time to Rise from Seated Position 
University of Alabama Pain Behavior Scales 
 Total Score 
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Research Question 3. The third research question was: Do the MMPI-2-RF’s 
substantive scales predict pain-related outcome at discharge in a low back pain patient 
sample? To this end, associations between the MMPI-2-RF substantive scales and 
outcome are examined in a structural equation modeling framework. All analyses were 
completed in Mplus. Version 6.11 (Muthén & Muthén, 2010) using the Maximum 
Likelihood (ML) estimator. Model fit was evaluated using the Comparative Fit Index 
(CFI; Bentler, 1990), the Tucker Lewis Index (TLI; Bentler & Bonett, 1980), and the 
Root Mean Square of Approximation (RMSEA; Steiger, 1998). CFI and TLI values 
greater than .95 and RMSEA values less than .05 are indicative of good fit (Bentler, 
1990; Browne, Cudeck, Bollen, & Long, 1993; Vandenberg & Lance, 2000; Yu, 2002).  
The first step of this set of analysis was to identify a measurement model for 
outcome. Items from the PDI, Physical Ability tests, and the UAB Pain Behavior Scale 
Total Score were used to model latent pain disability and physical ability factors at intake 
and discharge. Pain disability is differentiated from physical ability in that the former 
might have a greater contribution from psychological factors. The hypothesized 
measurement model is presented in Figure 1. Once adequate fit for the initial 
measurement model was achieved, measurement invariance testing was conducted to 
confirm that the latent constructs do not differ across time or by gender. 
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Figure 1. Hypothesized Measurement Model 
Pain Disability
Discharge
Physical 
Ability
Discharge
Pain Disability
Intake
Physical 
Ability
Intake
PDI1 PDI2 PDI… PDI… PDI2 PDI1
UAB REACH STAIRS STAIRS REACH UAB
 
Note. The Pain Disability Index (PDI) has seven scales. UAB (University of Alabama Pain Behavior Rating Scales). 
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The most basic type of measurement invariance is configural invariance (Kline, 
2011). When configural invariance is achieved, it indicates that the latent constructs are 
stable and their indicators are similar across gender and time points. If the CFI difference 
between the full sample model and alterative models with males only and/or females only 
was more than .010, this finding would indicate that the model does not meet configural 
invariance (Cheung & Rensvold, 2002). Configural invariance across time is identified 
by a qualitative comparison of indicator factor loadings, with similar factor loadings 
across time supporting configural invariance (Little, 2013). If configural invariance was 
not indicated for either gender or time, the measurement model would need to be re-
specified. 
Weak invariance is achieved if the factor loadings are not significantly different 
across time points and by gender. It was tested by constraining the factor loadings to be 
equal across time and by gender. A difference in CFI of more than .010 indicates that the 
model does not meet weak factorial invariance, which means the factor loadings are not 
equal across time or by gender. If weak factorial invariance was not achieved, partial 
measurement invariance was tested by releasing individual indicators across groups 
and/or time points using modification indices information until potential indicators with 
substantially different loadings (i.e., differential functioning indicators) were isolated.  
Strong invariance is present if both factor loadings and intercepts are equivalent 
across time and by gender. It was tested by constraining factor loadings and intercepts to 
be equal across time and by gender. Here too, a difference in CFI of more than .010 
indicates that the model does not meet strong invariance. However, the model would not 
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be re-specified if it did not meet strong invariance, as this is a strict form of measurement 
invariance that is unlikely to impact the results (Kline, 2011).  
After the measurement model was finalized, MMPI-2-RF substantive scales were 
entered into the model and correlated with the outcome variables. Because the MMPI-2-
RF scales have item overlap across scale sets, the Higher-Order, RC, Specific Problem, 
and PSY-5 Scales were entered into the model separately. Entering these scale sets into 
the model simultaneously would violate the assumption of independence of error terms, 
as some MMPI-2-RF scales would necessarily correlate with each other because they 
share the same items (Kline, 2011). At this stage of the data analysis, model fit was likely 
to be extremely poor because even MMPI-2-RF scales that are not expected to correlate 
with outcome were entered into the model. This approach is preferable to only entering in 
scales likely to correlate with outcome for two reasons: (a) it allows for examination of 
discriminant validity of the instrument; and (b) because the MMPI-2-RF is a new 
instrument with no research in this setting, it is desirable to take an exploratory approach 
to data analysis. Consequently, model fit was not informative in this context and was not 
considered. It was hypothesized that scales from the MMPI-2-RF’s Internalizing and 
Thought Dysfunction domains would have significant correlations with pain-related 
outcomes given the prominence of mood and cognitions in the bio-psycho-social model 
of pain (Gatchel et al., 2007). It was further hypothesized that scales in the interpersonal 
functioning domain would have significant correlations with outcome, as interpersonal 
deficits may interfere with the acquisition and use of social support, as well as activities 
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of daily living, all of which are indicated by the social component of the bio-psycho-
social model of pain.  
 
Research Question 4. The fourth research question was: Do the RC Scales 
demonstrate improved interpretive utility compared to the MMPI-2’s Clinical Scales 
among groups of low back pain patients presenting with the following: depression, 
substance use disorder, and no mental disorder? All patients were evaluated for 
Diagnostic and Statistical Manual-IV-TR (DSM-IV-TR; APA, 2000) disorders by 
licensed clinical psychologists. Patients with a Major Depressive Disorder or Dysthymia 
diagnosis were classified in the depressed group, and individuals with alcohol or illicit 
drug abuse or dependence diagnoses were assigned to the substance use disorder group. 
Individuals with diagnoses of Bipolar Disorder, Post-Traumatic Stress Disorder, 
Somatization Disorder, Conversion Disorder, or anxiety disorders were excluded from 
these groups. The final group of patients included those who were not diagnosed with a 
DSM-IV-TR mental disorder. The three groups were mutually exclusive.  
Mean profiles and elevation rates were compared across the two sets of scales in 
each diagnostic group. I expected the findings to illustrate the improved discriminant 
validity of the RC Scales compared to the Clinical Scales. I hypothesized that mean RC 
Scale scores would be more consistent with theoretical expectations than the Clinical 
Scale mean scores. Specifically, based on the previously described findings by McCord 
and Drerup (2011), I expected the depressed group would have mean profile elevations 
(i.e., > 65T) on Clinical Scales 1, 2, 3, 4, 7, and 8, whereas I hypothesized the RC Scales 
would produce mean elevations on only RCd, RC1, and RC2. In the Substance Use 
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group, I expected mean profile elevations on Clinical Scales 1, 2, 3, 4, 8, and 9 because 
scales 1, 2, and 3 are associated with chronic pain patient profiles and scales 4, 8 and 9 
are correlated with externalizing behaviors. However, I expected this group to produce 
mean elevations on only on RC1 and RC4. Finally, in the no diagnosis group I expected 
mean elevations on Clinical Scales 1, 2, and 3 and RC1. I also hypothesized that 
elevation rates among scales that are not associated with the group’s diagnosis would be 
significantly higher among the Clinical Scales at a range of cutoffs from 60T to 90T, 
though I expected that the MMPI-2-RF would produce significantly less elevations on 
scales that are associated with the group’s diagnosis (e.g., RC2 versus Scale 2 in the 
depressed group). I hypothesized that significantly higher elevation rates would occur 
among the Clinical Scales in the group with no mental disorder diagnosis, reflecting 
limited discriminant validity. 
 To further contrast the discriminant properties of the RC and Clinical Scales, I 
compared mean profiles and elevation rates across diagnostic groups for each set of 
scales.  Here too I expected the RC Scales would yield more theoretically appropriate 
discrimination than the Clinical Scales. Among the RC Scales, I hypothesized that the 
depressed group would score significantly higher on RCd, RC2, and RC7 and that the 
substance use group would score significantly higher on RC4 compared to the other 
groups. For the Clinical Scales, I expected that the depressed group would score higher 
on scales 2 and 7 and that the substance use group would score significantly higher on 
scale 4; however, I also expected significant differences across groups on scales that are 
not as relevant to that group’s diagnosis (i.e., the remaining Clinical Scales). I also 
  
46 
 
expected the RC Scales would yield more theoretically appropriate discrimination than 
the Clinical Scales when comparing elevation rates across diagnoses. More specifically, I 
hypothesized that the depressed group would produce significantly higher elevation rates 
on RCd, RC2, and RC7 and that the substance use group would have higher elevation 
rates on RC4 compared to the other groups. For the Clinical Scales, I expected that the 
depressed group would have higher elevation rates on scales 2 and 7 and that the 
substance use group would have more elevations on scale 4; however, I also expected 
significant elevation rate differences across groups on scales that are not as relevant to 
that group’s diagnosis.  
 
Power Analysis 
 According to G*Power 3.17 (Faul, Erdfelder, Lang, & Buchner, 2007), a sample 
size of 134 was necessary for the correlational analyses to identify a medium effect size 
(i.e., r > .30, respectively) with a power of .95. For the structural equation modeling 
analyses, the hypothesized measurement model had 156 degrees of freedom, which 
according to MacCallum, Browne, and Sugawara (1996) required a sample size of 176.56 
in order to identify a close-fitting model (i.e., a model with an RMSEA of .05).  
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RESULTS 
 
Descriptive Findings 
 Means and standard deviation for all MMPI-2-RF validity and substantive scales 
are presented for the full sample and by gender in Table 5. Mean differences between 
genders of five or more T-score points (i.e., one-half standard deviation in the general 
population) are considered clinically meaningful, consistent with traditional benchmarks 
for the interpretation of the MMPI-2 and MMPI-2-RF (Graham, 2012). Clinically 
meaningful gender differences were found on the following scales: Infrequent Somatic 
Responses (Fs), Symptom Validity (FBS-r), Behavioral/Externalizing Dysfunction 
(BXD), Antisocial Behavior (RC4), Gastrointestinal Complaints (GIC), Multiple Specific 
Fears (MSF), Juvenile Conduct Problems (JCP), Substance Abuse (SUB), Aesthetic-
Literary Interests (AES), Mechanical-Physical Interests (MEC), Aggressiveness-Revised 
(AGGR-r), Disconstraint-Revised (DISC-r). Men scored higher than women on BXD, 
RC4, JCP, SUB, MEC, AGGR-r, and DISC-r, whereas women scored higher than men 
on Fs, FBS-r, GIC, MSF, and AES. Differences between genders were most pronounced 
on MEC (men scored 13T higher than women). Both genders produced mean substantive 
scale clinical elevations (i.e., a score > 65T) on Somatic Complaints (RC1), Malaise 
(MLS), and Neurological Complaints (NUC), and women additionally had a mean 
elevation on Gastrointestinal Complaints (GIC). 
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Table 5. MMPI-2-RF Means and Standard Deviations by Gender 
 Men 
(n = 318) 
Women 
(n = 493) 
Overall 
(N=811) 
Scales M SD M SD M SD 
Validity Scales       
Variable Response Inconsistency (VRIN-r) 51 9 52 10 52 10 
True Response Inconsistency (TRIN-r) 51F 9 51F 11 51F 10.0 
Infrequent Responses (F-r) 70 16 70 16 70 16 
Infrequent Psychopathology Responses (FP-r) 53 11 53 11 53 11 
Infrequent Somatic Responses (FS) 62 16 67 19 65 18 
Symptom Validity (FBS-r) 68 13 75 13 72 13 
Response Bias Scale (RBS) 64 15 68 15 66 15 
Uncommon Virtues (L-r) 55 11 55 9 55 10 
Adjustment Validity (K-r) 48 10 47 9 47 9 
Higher-Order       
Emotional/Internalizing Dysfunction (EID) 61 12 63 11 62 12 
Thought Dysfunction (THD) 51 10 54 11 53 11 
Behavioral/Externalizing Dysfunction (BXD) 55 11 46 9 49 10 
Restructured Clinical       
Demoralization (RCd) 61 12 64 11 63 11 
Somatic Complaints (RC1) 69 11 73 12 72 11 
Low Positive Emotions (RC2) 64 13 63 12 63 12 
Cynicism (RC3) 49 10 48 10 49 10 
Antisocial Behavior (RC4) 56 11 49 9 52 11 
Persecutory Ideation (RC6) 53 11 54 11 54 11 
Dysfunctional Negative Emotions (RC7) 52 11 55 11 53 11 
Aberrant Experiences (RC8) 52 10 54 11 53 11 
Hypomanic Activation (RC9) 48 10 45 8 46 9 
Specific Problems       
Malaise (MLS) 77 8 77 8 77 8 
Gastrointestinal Complaints (GIC) 61 16 67 17 64 17 
Head Pain Complaints (HPC) 63 9 66 10 65 10 
Neurological Complaints (NUC) 70 13 71 13 71 13 
Cognitive Complaints (COG) 60 14 64 14 62 14 
       
Suicidal Ideation (SUI) 57 17 56 17 57 17 
Helplessness (HLP) 54 14 54 12 54 13 
Self-Doubt (SFD) 57 12 59 12 58 12 
Inefficacy (NFC) 52 11 55 12 54 12 
Stress/Worry (STW) 55 12 57 11 56 11 
Anxiety (AXY) 56 15 59 14 58 14 
Anger Proneness (ANP) 54 12 53 11 53 11 
Behavior Restricting Fears (BRF) 51 9 55 12 53 11 
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 Men 
(n = 318) 
Women 
(n = 493) 
Overall 
(N=811) 
Scales M SD M SD M SD 
Multiple Specific Fears (MSF) 46 7 54 10 51 10 
       
Juvenile Conduct Problems (JCP) 55 13 49 10 51 12 
Substance Abuse (SUB) 54 11 48 8 50 10 
Aggression (AGG) 51 11 48 8 49 10 
Activation (ACT) 46 9 49 10 48 10 
       
Family Problems (FML) 50 11 54 12 52 12 
Interpersonal Passivity (IPP) 49 10 53 10 51 10 
Social Avoidance (SAV) 56 11 52 11 54 11 
Shyness (SHY) 51 11 51 10 51 10 
Disaffiliativeness (DSF) 54 14 51 11 52 12 
       
Aesthetic-Literary Interests (AES) 42 9 47 9 45 9 
Mechanical-Physical Interests (MEC) 57 10 44 6 49 10 
Personality-Psychopathology-5       
Aggressiveness-Revised (AGGR-r) 51 10 46 8 48 9 
Psychoticism-Revised (PSYC-r) 52 10 54 10 53 10 
Disconstraint-Revised (DISC-r) 55 11 44 7 48 10 
Negative Emotionality/Neuroticism-Revised 
(NEGE-r) 
56 13 58 12 
57 12 
Introversion/Low Positive Emotionality-Revised 
(INTR-r) 
60 13 57 12 
58 12 
Note. M (Mean); SD (Standard Deviation).  
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Reliability 
 Mean inter-item correlations, Cronbach’s alpha internal consistency, and standard 
error of measurement estimates are provided in Table 6 for all substantive scales. Also 
included are comparable estimates in the MMPI-2-RF normative sample (Tellegen & 
Ben-Porath, 2008/2011). 
Internal consistency estimates for the Higher-Order Scales ranged from .67 
(Thought Dysfunction) to .90 (Emotional/Internalizing Dysfunction) with a median of 
.79. Among the Restructured Clinical Scales, reliability estimates ranged from .61 
(Persecutory Ideation) to .90 (Demoralization) with a median of .77. For the Specific 
Problems Scales, internal consistency ranged from .46 (Behavior Restricting Fears) to .80 
(Social Avoidance) with a median of .67. Finally, among the Personality-
Psychopatology-5 Scales, internal consistency ranged from .65 (Psychoticism-Revised) to 
.80 (Negative Emotionality/Neuroticism-Revised) with a median of .77. Overall, internal 
consistency estimates were consistent with the normative sample, except for Malaise, 
which had a substantially lower estimate (> .10) in this sample.  
Mean inter-item correlations for the broadest level of measurement, the Higher-
Order Scales, ranged from .07 (Thought Dysfunction) to .19 (Emotional/Internalizing 
Dysfunction) with a median of .14. Among the Restructured Clinical Scale, mean inter-
item correlation estimates ranged from .08 (Persecutory Ideation) to .28 (Demoralization) 
with a median of .13. For the shortest scales, the Specific Problems Scales, mean inter-
item correlations ranged from .09 (Anger Proneness) to .43 (Self Doubt) with a median of 
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.22. Finally, among the Personality-Psychopatology-5 Scales, mean inter-item 
correlations ranged from .07 (Psychoticism-Revised) to .16 (Negative 
Emotionality/Neuroticism-Revised and Introversion/Low Positive Emotionality-Revised) 
with a median of .14. Overall, mean inter-item correlations were generally consistent 
with the normative sample, except for the following scales that had appreciably lower (> 
.05) estimates: Malaise and Head Pain Complaints.   
Also provided in Table 6 are standard errors of measurement for all substantive 
scales. For the Higher-Order Scales, standard error of measurements (expressed in T 
score units) ranged from 3.7 (Emotional/Internalizing Dysfunction) to 6.1 (Thought 
Dysfunction) with a median of 4.7. Among the Restructured Clinical Scales, standard 
errors of measurement ranged from 3.6 (Demoralization) to 6.9 (Persecutory Ideation) 
with a median of 5.1. For the Specific Problems Scales, standard errors of measurement 
ranged from 5.1 (Multiple Specific Fears) to 9.7 (Suicidal Ideation) with a median of 6.1. 
Finally, among the Personality-Psychopatology-5 Scales, standard errors of measurement 
ranged from 4.8 (Aggressiveness-Revised) to 6.1 (Psychoticism-Revised) with a median 
of 5.5. Overall, the estimates for the substantive scales were consistent with those 
obtained in the normative sample, except for Gastrointestinal Complaints, Cognitive 
Complaints, Suicidal Ideation, and Anxiety which had substantially higher SEM 
estimates (> 1T) in this sample. 
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Table 6. MMPI-2-RF Reliability Estimates in Chronic Pain and Normative Samples 
Scale Name 
Mean 
Inter-Item 
Correlation 
Mean Inter-
Item 
Correlation 
(Normative 
Sample) 
Internal 
Consistency 
Internal 
Consistency 
(Normative 
Sample) 
Standard 
Error of 
Measurement 
Standard 
Error of 
Measurement 
(Normative 
Sample) 
Number 
of 
Items 
Higher-Order      
 
 
Emotional/Internalizing 
Dysfunction (EID) .19 .15 .90 .87 3.7 3.6 41 
Thought Dysfunction 
(THD) .07 .08 .67 .69 6.1 5.6 26 
Behavioral/Externalizing 
Dysfunction (BXD) .14 .14 .79 .76 4.7 4.7 23 
Restructured Clinical        
Demoralization (RCd) .28 .24 .90 .88 3.6 3.3 24 
Somatic Complaints 
(RC1) .13 .11 .80 .76 5.1 4.7 27 
Low Positive Emotions 
(RC2) .13 .10 .71 .66 6.4 5.9 17 
Cynicism (RC3) .21 .21 .80 .80 4.4 4.5 15 
Antisocial Behavior (RC4) .13 .13 .77 .75 5.2 4.8 22 
Persecutory Ideation 
(RC6) .08 .09 .61 .65 6.9 5.9 17 
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Scale Name 
Mean 
Inter-Item 
Correlation 
Mean Inter-
Item 
Correlation 
(Normative 
Sample) 
Internal 
Consistency 
Internal 
Consistency 
(Normative 
Sample) 
Standard 
Error of 
Measurement 
Standard 
Error of 
Measurement 
(Normative 
Sample) 
Number 
of 
Items 
Dysfunctional Negative 
Emotions (RC7) .18 .16 .84 .82 4.5 4.0 24 
Aberrant Experiences 
(RC8) .12 .11 .72 .71 5.7 5.5 18 
Hypomanic Activation 
(RC9) .10 .11 .76 .78 4.3 4.7 28 
Specific Problems        
Malaise (MLS) .10 .19 .47 .62 5.5 5.9 8 
Gastrointestinal 
Complaints (GIC) .32 .27 .70 .67 9.1 5.8 5 
Head Pain Complaints 
(HPC) .22 .27 .63 .64 5.9 6.0 6 
Neurological Complaints 
(NUC) .17 .11 .67 .55 7.7 6.7 10 
Cognitive Complaints 
(COG) .24 .16 .76 .67 6.9 5.8 10 
        
Suicidal Ideation (SUI) .29 .16 .67 .38 9.7 7.9 5 
Helplessness (HLP) .24 .15 .61 .45 8.0 7.5 5 
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Scale Name 
Mean 
Inter-Item 
Correlation 
Mean Inter-
Item 
Correlation 
(Normative 
Sample) 
Internal 
Consistency 
Internal 
Consistency 
(Normative 
Sample) 
Standard 
Error of 
Measurement 
Standard 
Error of 
Measurement 
(Normative 
Sample) 
Number 
of 
Items 
Self-Doubt (SFD) .43 .38 .75 .70 6.0 5.5 4 
Inefficacy (NFC) .26 .22 .76 .71 5.7 5.4 9 
Stress/Worry (STW) .18 .16 .61 .56 7.1 6.3 7 
Anxiety (AXY) .20 .15 .55 .44 9.5 7.5 5 
Anger Proneness (ANP) .28 .27 .73 .72 5.8 5.4 7 
Behavior Restricting Fears 
(BRF) .09 .09 .46 .47 8.3 7.3 9 
Multiple Specific Fears 
(MSF) .22 .25 .71 .70 5.1 5.0 9 
        
Juvenile Conduct 
Problems (JCP) .29 .24 .71 .61 6.3 6.3 6 
Substance Abuse (SUB) .20 .20 .64 .62 6.0 5.9 7 
Aggression (AGG) .16 .16 .63 .62 5.8 6.1 9 
Activation (ACT) .15 .15 .58 .60 6.4 6.3 8 
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Scale Name 
Mean 
Inter-Item 
Correlation 
Mean Inter-
Item 
Correlation 
(Normative 
Sample) 
Internal 
Consistency 
Internal 
Consistency 
(Normative 
Sample) 
Standard 
Error of 
Measurement 
Standard 
Error of 
Measurement 
(Normative 
Sample) 
Number 
of 
Items 
        
Family Problems (FML) .20 .16 .71 .66 6.2 5.9 10 
Interpersonal Passivity 
(IPP) .18 .19 .69 .70 5.7 5.6 10 
Social Avoidance (SAV) .29 .26 .80 .78 5.0 4.8 10 
Shyness (SHY) .32 .31 .77 .76 5.0 4.7 7 
Disaffiliativeness (DSF) .18 .13 .57 .47 8.0 7.3 6 
        
Aesthetic-Literary 
Interests (AES) .17 .17 .58 .55 6.1 6.3 7 
Mechanical-Physical 
Interests (MEC) .25 .24 .75 .59 5.1 4.8 9 
Personality-
Psychopathology-5        
Aggressiveness-Revised 
(AGGR-r) .13 .14 .73 .73 4.8 5.3 18 
Psychoticism-Revised 
(PSYC-r) .07 .08 .65 .69 6.1 5.6 26 
Disconstraint-Revised 
(DISC-r) .14 .14 .77 .71 4.9 4.9 20 
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Scale Name 
Mean 
Inter-Item 
Correlation 
Mean Inter-
Item 
Correlation 
(Normative 
Sample) 
Internal 
Consistency 
Internal 
Consistency 
(Normative 
Sample) 
Standard 
Error of 
Measurement 
Standard 
Error of 
Measurement 
(Normative 
Sample) 
Number 
of 
Items 
Negative 
Emotionality/Neuroticism-
Revised (NEGE-r) .16 .14 .80 .77 5.5 4.8 20 
Introversion/Low Positive 
Emotionality-Revised 
(INTR-r) .16 .13 .79 .75 5.7 5.0 20 
 57 
 
 
 
Concurrent External Correlates 
Zero-order correlations between MMPI-2-RF substantive scales and external chart 
review, PDI, and DASS criteria are presented in Table 7 for the Higher-Order, 
Restructured Clinical, and Somatic/Cognitive Specific Problem Scales, in Table 8 for the 
Internalizing and Externalizing Specific Problem Scales, and in Table 9 for the 
Interpersonal Specific Problem Scales, Interest Scales, and Pesonality-Psychopathology-5 
Scales. I applied a family-wise Bonferroni correction to reduce the risk of Type I error, 
which yielded a corrected alpha level of .001 (.05 / 33 comparisons for each scale). Only 
correlations that met this alpha level were interpreted. In order to facilitate interpretation, 
the findings are summarized in reference to each of the five MMPI-2-RF domains, which 
include: (1) Emotional Dysfunction; (2) Thought Dysfunction; (3) Behavioral 
Dysfunction; (4) Somatic/Cognitive Complaints; and (5) Interpersonal Functioning.  
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Table 7. MMPI-2-RF Higher Order, Restructured Clinical, and Somatic/Cognitive Specific Problem Scale Correlations with 
Concurrent Criteria and Outcome 
  Higher-Order Restructured Clinical Somatic/Cognitive 
 n EID THD BXD RCd RC1 RC2 RC3 RC4 RC6 RC7 RC8 RC9 MLS GIC HPC NUC COG 
Medical Record 
Criteria 
  
                 
Duration of pain 672 .02 .08* -.06 .06 .11** -.01 .00 .00 .05 .01 .04 -.04 .04 .08* .07 .02 .06 
Current Smoker 155 .08 .15 .36*** .07 .03 .12 .23** .37*** .20* .12 .13 .17* .07 -.04 .04 .09 .06 
Pain Intensity 
Rating 747 -.01 .11** -.06 -.03 .12*** -.05 .09* -.07 .05 .00 .12** -.04 .09* .03 .08* .14*** .06 
Number of 
Narcotic Pain 
Medications 743 -.02 -.01 .02 .00 -.04 -.06 -.03 .00 .02 -.06 -.04 .03 .02 .03 -.12*** .00 -.04 
Number of 
Antidepressants 743 .15*** .02 -.04 .18*** .13*** .05 -.04 .01 .02 .09* .04 -.01 .10** .06 .10** .08* .12** 
Number of 
Antipsychotics 743 .09* .09* .02 .11** .08* .07 .08* .04 .04 .10** .11** .07 .06 .02 .08* .08* .09* 
Number of 
Sleeping 
Medications 743 .02 .00 -.05 .07* .03 .00 -.01 -.02 -.05 -.03 .03 -.06 .02 .01 .06 .02 .01 
Number of 
Benzodiazepines 743 .11** .09* -.03 .11** .14*** .06 -.03 -.01 .09* .10** .09* .03 .10** .10** .07 .14*** .11** 
Years since Last 
Employment 623 .05 .05 -.06 .04 .09* .04 -.03 -.02 -.03 .03 .06 -.02 .05 .04 .01 .11** .09* 
Hours Resting 
per Day 655 .15*** .00 -.04 .14*** .13*** .18*** .01 .00 .01 .07 .03 -.04 .22*** .11** .05 .16*** .11** 
DSM-IV 
Diagnoses                    
Substance Use 712 .12** .10* .43*** .15*** .08* .06 .08* .48*** .11** .10** .14*** .16*** .08* .11** .03 .08* .05 
Major 
Depressive 
Disorder 748 .29*** .15*** -.06 .31*** .19*** .19*** .05 -.07 .05 .25*** .18*** .03 .17*** .15*** .13*** .11** .18*** 
Anxiety 
Disorder 797 .10** .05 -.08* .09* .09** .07* .00 -.06 .04 .09* .06 -.04 .12** .03 .06 .04 .07* 
Somatoform 
Disorder 781 .01 .16*** .01 .04 .12*** -.01 .01 .02 -.01 .03 .18*** .02 .05 .04 .11** .08* .06 
Bipolar Disorder 790 .10** .13*** .13*** .10** .00 .09* .12*** .18*** .12*** .12*** .15*** .12** .01 .01 .02 .00 .07* 
Post-Traumatic 
Stress Disorder 799 .06 .13*** .16*** .08* .12** .06 .06 .14*** .15*** .09* .14*** .14*** .05 .07* .11** .07* .11** 
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  Higher-Order Restructured Clinical Somatic/Cognitive 
 n EID THD BXD RCd RC1 RC2 RC3 RC4 RC6 RC7 RC8 RC9 MLS GIC HPC NUC COG 
Pain Disability 
Index (PDI)                   
Total Score 719 .16*** .11** -.05 .15*** .24*** .16*** .07 -.02 .04 .05 .14*** -.06 .27*** .10** .14*** .26*** .15*** 
Family/Home 
615 .12** .07 
-
.14*** .09* .17*** .10* .05 -.11** .03 .03 .09* -.08* .24*** .06 .12** .18*** .12** 
Recreation 615 .06 .05 -.05 .06 .12** .05 .01 -.05 .06 -.01 .06 -.01 .17*** .02 .10* .15*** .06 
Socialization 615 .13** .06 -.09* .13** .14*** .14*** .05 -.09* .01 .01 .09* -.06 .19*** .07 .10* .10* .08* 
Occupation 610 .13*** .06 .02 .12** .12** .14*** .01 .04 .04 .06 .09* -.02 .17*** .05 .10* .15*** .13** 
Sexual 603 .09* .02 -.05 .09* .15*** .10* .04 -.02 -.04 -.01 .06 -.07 .13** .06 .06 .17*** .07 
Self-Care 615 .11** .13** -.01 .12** .22*** .12** .10* .03 .07 .04 .13*** -.06 .21*** .07 .12** .23*** .11** 
Life Support 616 .08* .13** .02 .11** .21*** .07 .12** .05 .04 .06 .18*** .00 .18*** .11** .16*** .22*** .11** 
Depression 
Anxiety Stress 
Scales (DASS)                   
Depression 255 .51*** .23*** .03 .55*** .27*** .32*** .22*** -.01 .21*** .35*** .26*** .17** .36*** .12 .18** .24*** .33*** 
Anxiety 255 .40*** .31*** -.06 .40*** .50*** .16* .20** -.06 .19** .45*** .37*** .17** .30*** .27*** .29*** .44*** .40*** 
Stress 210 .47*** .26*** .04 .47*** .28*** .25*** .24*** .00 .26*** .47*** .29*** .27*** .31*** .23*** .15* .19** .29*** 
Physical Ability 
Tests                   
Time to Rise 
from Seated 
Position 501 -.02 -.01 -.12** -.03 .04 .02 .03 -.11* -.01 -.01 -.02 -.07 -.07 -.02 -.04 .11* .05 
Number of Stairs 
Climbed in One 
Minute 480 -.03 -.09 .08 .00 -.12** -.06 -.11* .05 -.06 -.06 -.06 .04 .00 .01 .01 -.26*** -.07 
Distance Walked 
in Six Minutes 549 .00 -.04 .03 -.03 -.02 .03 .01 -.01 -.04 -.01 -.04 -.02 -.08 -.03 .03 -.05 -.02 
Functional 
Reach in Inches 460 -.04 -.07 .10* -.01 -.09* -.09* -.01 .08 .02 -.05 -.10* .06 -.01 .04 -.02 -.18*** -.08 
University of 
Alabama Pain 
Behavior Scales                   
Total Score 617 .04 .06 -.02 .04 .11** .03 .11** -.03 .07 .03 .07 .05 .07 -.03 .00 .24*** .09* 
Outcome                   
Poor Physical 
Ability 800 -.09 .12* -.16** -.07 -.08 .00 .01 -.20** .00 .00 .20** -.05 -.02 -.17** .00 .06 -.03 
Pain Disability 800 .02 .06 .03 -.02 .03 .10 -.09 .00 .00 -.13 .12* -.03 .10 -.07 -.05 .08 .10 
  
60 
 
Note. 
*
 p < .05, 
**
 p <.01(p <.025 for  outcome variables), 
***
 p < .001. EID (Emotional/Internalizing Dysfunction); THD 
(Thought Dysfunction); BXD (Behavioral/Externalizing Dysfunction); RCd (Demoralization); RC1 (Somatic Complaints); 
RC2 (Low Positive Emotions); RC3 (Cynicism); RC4 (Antisocial Behavior); RC6 (Ideas of Persecution); RC7 (Dysfunctional 
Negative Emotions); RC8 (Aberrant Experiences); RC9 (Hypomanic Activation); MLS (Malaise); GIC (Gastrointestinal 
Complaints); HPC (Head Pain Complaints); NUC (Neurological Complaints); COG (Cognitive Complaints).  
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Table 8. MMPI-2-RF Internalizing and Externalizing Specific Problem Scale Correlations with Concurrent Criteria and 
Outcome 
 n Internalizing Externalizing 
   SUI HLP SFD NFC STW AXY ANP BRF MSF JCP SUB AGG ACT 
Medical Record Criteria               
Duration of pain 672 .01 -.04 .05 .03 .01 .00 -.01 .09* .03 .00 .02 -.09* -.01 
Current Smoker 155 .18* .13 .02 .08 .09 .12 .08 .06 -.03 .30*** .27*** .18* .11 
Pain Intensity Rating 747 -.01 .02 .01 .04 .00 .01 .05 .06 .06 -.02 -.09* -.04 .01 
Number of Narcotic Pain 
Medications 743 .09* .00 .01 -.05 -.04 -.01 -.03 -.08* -.06 -.07* .08* .00 -.03 
Number of Antidepressants 743 .10** .07 .17*** .11** .12*** .14*** .04 .09* .06 -.04 .05 -.01 -.01 
Number of Antipsychotics 743 .04 .08* .08* .09** .14*** .13*** .09* .08* .04 -.01 .01 .08* .01 
Number of Sleeping 
Medications 743 .01 -.01 .05 .05 .02 .04 -.04 -.05 .00 .00 .02 -.06 .01 
Number of Benzodiazepines 743 .10** .06 .06 .09* .16*** .17*** .04 .08* .05 -.03 .00 .02 .06 
Years since Last 
Employment 623 .00 .03 .06 .06 -.02 -.01 -.02 .09* .13** .05 -.05 -.05 .05 
Hours Resting per Day 655 .14*** .13*** .15*** .08* .01 .08* -.02 .06 .01 -.02 .01 .00 -.05 
DSM-IV Diagnoses                
Substance Use 712 .17*** .06 .12** .06 .02 .14*** .10** .02 -.13*** .30*** .59*** .20*** .02 
Major Depressive Disorder 748 .18*** .20*** .25*** .19*** .21*** .20*** .14*** .14*** .04 -.07 -.09* .05 .00 
Anxiety Disorder 797 .03 .07* .09* .05 .16*** .16*** .04 .04 .00 -.03 -.08* -.02 -.01 
Somatoform Disorder 781 .05 .04 .02 .02 .05 .07* .03 -.04 .02 .01 .00 .00 .06 
Bipolar Disorder 790 .09* .06 .07 .08* .10** .14*** .07 .05 .02 .12*** .10** .14*** .08* 
Post-Traumatic Stress 
Disorder 799 .06 .02 .04 .08* .03 .19*** .09** .05 .01 .15*** .04 .16*** .08* 
Pain Disability Index (PDI)               
Total Score 719 .15*** .12** .11** .04 .06 .12** .05 .07 -.02 -.02 -.10** .01 .00 
Family/Home 615 .09* .12** .07 .02 .07 .03 .03 .02 .02 -.09* -.18*** -.05 -.02 
Recreation 615 .08 .04 .05 -.04 .04 .02 .03 .01 -.03 -.04 -.14*** -.02 -.02 
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 n Internalizing Externalizing 
   SUI HLP SFD NFC STW AXY ANP BRF MSF JCP SUB AGG ACT 
Socialization 615 .12** .05 .07 -.03 .06 .06 .04 .03 -.03 -.07 -.11** -.01 -.05 
Occupation 610 .11** .09* .07 .07 .05 .07 .08 .03 -.02 .01 .00 .05 -.05 
Sexual 603 .16*** .08 .08 -.06 .00 .03 .02 -.02 -.03 -.02 -.04 .02 -.05 
Self-Care 615 .11** .11** .08 .04 .02 .07 .03 .04 .00 .03 -.06 -.03 -.01 
Life Support 616 .11** .06 .05 .01 .02 .11** .07 .12** -.02 .02 -.02 .03 .02 
Depression Anxiety Stress 
Scales (DASS)               
Depression 255 .27*** .35*** .42*** .29*** .41*** .34*** .25*** .24*** .05 -.02 -.05 .22*** .18** 
Anxiety 255 .21*** .21*** .32*** .37*** .48*** .48*** .26*** .39*** .18** -.07 -.12 .15* .25*** 
Stress 210 .13 .18* .29*** .26*** .44*** .38*** .47*** .22** .05 .02 -.10 .28*** .32*** 
Physical Ability Tests               
Time to Rise from Seated 
Position 501 .02 .02 .01 .05 -.03 -.04 -.04 .06 .08 -.08 -.10* -.05 .00 
Number of Stairs Climbed in 
One Minute 480 -.07 -.07 -.01 -.06 -.03 -.01 .04 -.11* -.15*** -.02 .11* -.01 -.05 
Distance Walked in Six 
Minutes 549 -.05 .01 -.02 .02 .01 -.01 .03 -.02 -.01 -.04 .04 -.04 -.04 
Functional Reach in Inches 460 -.03 -.08 -.02 -.11* -.01 .02 .01 -.17*** -.19*** .03 .12* -.02 -.01 
University of Alabama 
Pain Behavior Scales               
Total Score 617 .07 .07 .01 .06 -.01 .02 .05 .04 .04 .01 -.09* .04 .08* 
Outcome               
Poor Physical Ability 800 -.02 .07 .03 .03 -.05 -.08 .08 .13 .08 -.09 .00 .13 .06 
Pain Disability 800 -.02 .18*** -.06 .02 -.15** -.03 .00 .05 -.03 -.01 .02 .03 .02 
Note. 
*
 p < .05, 
**
 p <.01(p <.025 for  outcome variables),, 
***
 p < .001. SUI (Suicidal/Death Ideation);HLP 
(Helplessness/Hopelessness); SFD (Self-Doubt); NFC (Inefficacy); STW (Stress/Worry); ANX (Anxiety); ANP (Anger 
Proneness); BRF (Behavior-Restricting Fears); MSF (Multiple Specific Fears); JCP (Juvenile Conduct Problems); SUB 
(Substance Abuse); AGG (Aggression); ACT (Activation).  
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Table 9. MMPI-2-RF Interpersonal Specific Problems, Interest, and Personality-Psychopathology-5 Scales Correlations with 
Concurrent Criteria and Outcome 
  Interpersonal  Interest  Personality-Psychopathology-5 
 n FML IPP SAV SHY DSF  AES MEC  AGGR-r PSYC-r DISC-r NEGE-r INTR-r 
Medical Record 
Criteria 
               
Duration of pain 672 .04 .02 -.01 -.02 .00  .08* -.04  -.05 .07 -.05 .02 .00 
Current Smoker 155 .15 -.14 .19* .08 .29***  -.25** .07  .19* .19* .31*** .08 .13 
Pain Intensity Rating 747 -.02 .00 -.04 -.01 -.03  .01 -.05  .01 .10** -.09* .04 -.04 
Number of Narcotic Pain 
Medications 743 -.02 -.03 -.05 -.07 -.03  .00 .05  .05 -.03 .02 -.05 -.05 
Number of 
Antidepressants 743 .11** .04 -.06 -.01 -.03  .08* -.10**  -.08* .03 -.05 .13*** .01 
Number of 
Antipsychotics 743 .06 -.01 -.02 .00 .00  .04 -.04  .05 .09* .00 .17*** .02 
Number of Sleeping 
Medications 743 .01 .02 -.01 -.05 -.02  .04 -.05  -.04 .01 -.06 .01 .02 
Number of 
Benzodiazepines 743 .11** .05 -.02 -.03 -.02  .09* -.05  -.04 .09** -.04 .14*** .01 
Years since Last 
Employment 623 .04 .08* -.06 .04 -.06  .01 -.07  -.07 .05 -.09* .05 -.02 
Hours Resting per Day 655 .01 .05 .09* .08 .10*  -.04 -.03  -.04 .03 -.03 .05 .15*** 
DSM-IV Diagnoses                 
Substance Use 712 .07 -.04 .07 .01 .13***  -.08* .22***  .10** .13*** .41*** .07 .06 
Major Depressive 
Disorder 748 .13*** .06 .10** .06 .07*  .03 -.11**  -.05 .14*** -.10** .24*** .15*** 
Anxiety Disorder 797 .02 .03 .02 .02 .07  .06 -.05  -.06 .04 -.07 .12** .05 
Somatoform Disorder 781 .06 -.03 -.04 -.04 -.01  .01 -.03  .00 .16*** .01 .02 -.03 
Bipolar Disorder 790 .13*** .02 .07* .03 .14***  .03 -.01  .03 .13*** .11** .11** .06 
Post-Traumatic Stress 799 .11** -.03 .04 -.04 .03  .00 .05  .06 .14*** .12*** .10** .02 
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  Interpersonal  Interest  Personality-Psychopathology-5 
 n FML IPP SAV SHY DSF  AES MEC  AGGR-r PSYC-r DISC-r NEGE-r INTR-r 
Disorder 
Pain Disability Index 
(PDI)                
Total Score 719 .10* .00 .10** -.02 .05  -.03 -.08*  .00 .12** -.08* .09* .15*** 
Family/Home 615 .01 -.04 .07 .02 .00  -.03 -.10*  .02 .07 -.15*** .10* .11** 
Recreation 615 .04 -.04 .06 -.03 .02  -.04 -.07  .04 .05 -.05 .05 .08* 
Socialization 615 .00 .00 .12** -.01 .06  -.05 -.08*  .00 .05 -.09* .07 .16*** 
Occupation 610 .09* .01 .12** .06 .05  -.06 .00  .02 .08 .01 .08 .15*** 
Sexual 603 .04 .03 .07 -.03 .03  -.09* -.03  -.03 .04 -.06 .02 .12** 
Self-Care 615 .06 -.05 .07 -.01 .04  .00 -.05  .03 .13*** -.03 .04 .11** 
Life Support 
616 .02 -.04 .05 
-
.10
*
 .05  -.01 -.01  .03 .12
**
 .00 .07 .06 
Depression Anxiety 
Stress Scales (DASS)                
Depression 255 .19** .02 .16* .12 .25***  -.05 .01  .03 .26*** -.03 .39*** .19** 
Anxiety 255 .20** .02 .09 .12 .17**  .09 -.08  .00 .33*** -.11 .50*** .07 
Stress 210 .31*** -.04 .19** .13 .22**  .02 -.01  .09 .26*** -.05 .51*** .16* 
Physical Ability Tests                
Time to Rise from 
Seated Position 501 -.01 .02 .02 .04 -.04  .03 .05  -.01 -.01 -.11* .01 .02 
Number of Stairs 
Climbed in One Minute 480 -.04 .01 .00 -.02 -.01  -.04 .05  -.02 -.06 .12** -.07 -.03 
Distance Walked in Six 
Minutes 549 -.07 .05 .06 .01 .02  .01 .08  -.03 -.02 .05 .01 .04 
Functional Reach in 
Inches 460 .01 -.05 .02 -.06 -.01  -.02 .11*  .04 -.05 .16*** -.05 -.04 
University of Alabama 
Pain Behavior Scales                
Total Score 
617 .01 -.05 -.02 -.01 .01  -.03 .07  .07 .05 -.04 .05 -.01 
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  Interpersonal  Interest  Personality-Psychopathology-5 
 n FML IPP SAV SHY DSF  AES MEC  AGGR-r PSYC-r DISC-r NEGE-r INTR-r 
Outcome 
               
Poor Physical Ability 
800 -.07 .03 -.08 .02 .03  .04 .00  -.10 .15
**
 -.13
*
 -.07 -.14
*
 
Pain Disability 
800 -.02 .01 .00 -.03 -.04  -.05 .02  .02 .14
**
 .02 -.10
**
 .11
**
 
Note. 
*
 p < .05, 
**
 p <.01 (p <.025 for  outcome variables), 
***
 p < .001. FML (Family Problems); IPP (Interpersonal Passivity); 
SAV (Social Avoidance); SHY (Shyness); DSF (Disaffiliativeness); Aesthetic-Literary Interests (AEC); Mechanical-Physical 
Interests (MEC); AGGR-r (Aggressiveness-Revised), PSYC-r (Psychoticism-Revised), DISC-r (Disconstraint-Revised), 
NEGE-r (Negative Emotionality/Neuroticism-Revised), INTR-r (Introversion/Low Positive Emotionality-Revised). 
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The scales in the Emotional Dysfunction domain include Higher-Order Scale 
Emotional/Internalizing Dysfunction (EID) and Restructured Clinical Scales 
Demoralization (RCd), Low Positive Emotions (RC2), and Dysfunctional Negative 
Emotions (RC7). This domain also includes the Internalizing Specific Problem Scales 
Suicidal/Death Ideation (SUI), Helplessness/Hopelessness (HLP), Self-Doubt (SFD), 
Inefficacy (NFC), Stress/Worry (STW), Anxiety (AXY), Anger Proneness (ANP), 
Behavior-Restricting Fears (BRF), and Multiple Specific Fears (MSF). Finally, this 
domain includes Personality-Psychopathology-5 Scales Negative 
Emotionality/Neuroticism-Revised (NEGE-r) and Low Positive 
Emotionality/Introversion-Revised (INTR-r). Scales in this domain demonstrated a 
number of convergent correlations with mental health history information. Many scales 
were associated with psychotropic medication use, including antidepressants (EID, RCd, 
SFD, STW, AXY, and NEGE-r) and benzodiazepines (STW, AXY, and NEGE-r), 
though some scales demonstrated correlations with antipsychotic medication use (STW, 
AXY, and NEGE-r). Scales in this domain were associated with mental health diagnoses, 
including major depressive disorder (EID, RCd, RC2, RC7, SUI, HLP, SFD, NFC, STW, 
AXY, ANP, BRF, NEGE-r, and INTR-r), bipolar disorder (RC7 and AXY), anxiety 
disorders (STW and AXY), and post-traumatic stress disorder (AXY). The Emotional 
Dysfunction domain’s scales correlated with the PDI (EID, RCd, RC2, SUI, and INTR-r), 
as well as the DASS (EID, RCd, RC2, RC7, SUI, HLP, SFD, NFC, STW, AXY, ANP, 
BRF, and NEGE-r). Regarding the DASS correlations, most scales demonstrated their 
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strongest correlations with DASS Depression (EID, RCd, RC2, SUI, HLP, SFD), though 
some scales correlated highest with DASS Anxiety (NFC, STW, AXY, and BRF) and 
DASS Stress (RC7, ANP, and NEGE-r). Many of the scales in this domain were 
associated with the number of hours resting per day (EID, RCd, RC2, SUI, HLP, SFD, 
and INTR-r). The MMPI-2-RF’s Emotional Dysfunction’s scales were generally 
uncorrelated with pain and physical ability tests.  
The scales in the Thought Dysfunction domain include Higher-Order Scale 
Thought Dysfunction (THD), Restructured Clinical Scales Persecutory Ideation (RC6) 
and Aberrant Experiences (RC8), and Personality-Psychopathology-5 Scale 
Psychoticism-Revised (PSYC-r). Scales in this domain were correlated with mental 
health diagnoses, including post-traumatic stress disorder and bipolar disorder (THD, 
RC6, RC8, and PSYC-r). These scales also demonstrated associations with somatoform 
disorder (THD, RC8, and PSYC-r), major depressive disorder (THD, RC8, and PSYC-r), 
and substance use disorder (RC8 and PSYC-r). As expected, some of the scales 
correlated with the PDI self-care and life support scales (RC8 and PSYC-r). All were 
correlated to some extent with the DASS Scales. The MMPI-2-RF’s Thought 
Dysfunction scales were generally uncorrelated with pain and physical ability tests. 
The scales in the Behavioral Dysfunction domain include Higher-Order Scale 
Behavioral/Externalizing Dysfunction (BXD), Restructured Clinical Scales Antisocial 
Behavior (RC4) and Hypomanic Activation (RC9), and the Externalizing Specific 
Problem Scales Juvenile Conduct Problems (JCP), Substance Abuse (SUB), Aggression 
(AGG), and Activation (ACT). This domain also includes Personality-Psychopathology-5 
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Scales Aggressiveness-Revised (AGGR-r) and Disconstraint-Revised (DISC-r). These 
scales demonstrated associations with mental health history information, particularly a 
history of substance use disorder (BXD, RC4, RC9, JCP, SUB, AGG, and DISC-r) and 
post-traumatic stress disorder (BXD, RC4, RC9, JCP, AGG, and DISC-r). Scales in this 
domain were also associated with smoking (BXD, RC4, JCP, SUB, and DISC-r). Some 
negative associations were demonstrated with pain disability (BXD, SUB, and DISC-r) 
and poor physical ability test results (DISC-r). Scales in this domain were generally 
uncorrelated with pain, internalizing problems, and narcotic medication use.  
The scales in the Somatic/Cognitive Complaints domain include Restructured 
Clinical Scale Somatic Complaints (RC1) and the Somatic/Cognitive Specific Problem 
Scales, which are comprised of Malaise (MLS), Gastrointestinal Complaints (GIC), Head 
Pain Complaints (HPC), Neurological Complaints (NUC), and Cognitive Complaints 
(COG). These scales demonstrated convergent associations with measures of pain, 
including pain intensity (RC1 and NUC) and the UAB (NUC). They were correlated with 
hours resting per day (RC1, MLS, and NUC) and the PDI scales (RC1, MLS, HPC, NUC, 
and COG). A number of associations were observed for medication use, including 
benzodiazepines (RC1 and NUC), antidepressants (RC1), and prescription narcotics 
(NUC). Specific Problem Scale Neurological Complaints (NUC) was negatively 
associated with functional reach and number of stairs climbed in one minute. All scales 
had some correlation with the DASS and demonstrated the strongest correlations with 
DASS Anxiety.  
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The scales in the Interpersonal Functioning domain include Restructured Clinical 
Scale Cynicism (RC3) and the Interpersonal Specific Problem Scales, which are 
comprised of Family Problems (FML), Interpersonal Passivity (IPP), Social Avoidance 
(SAV), Shyness (SHY), and Disaffiliativeness (DSF). These scales generally lacked 
meaningful associations with external criteria, though RC3, FML, and DSF were 
associated with Bipolar Disorder and some DASS scales. Disaffiliativeness (DSF) also 
had significant correlations with smoking and substance use.  
 
MMPI-2-RF Associations with Outcome 
 
 Measurement Model. The hypothesized measurement model is presented in 
Figure 1. Results indicated that this model fit the data adequately (CFI = .93, TLI = .92, 
RMSEA = .053). Modification indices showed that model fit could be improved by 
correlating the residual variance of PDI life support and PDI self-care at discharge (MI = 
108.4). I respecified the model to include this correlation, and modification indices 
showed that model fit could be further improved by correlating the residual variance of 
those variables at intake (MI = 71.4). I respecified the model to include this correlation. 
The final measurement model had good fit (CFI = .97, TLI = .96, RMSEA = .037) and is 
presented in Figure 2. Intercorrelations for the variables included in the model are 
presented in Table 10. 
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Figure 2. Final Measurement Model. 
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Table 10. Means, Standard Deviations, and Intercorrelations for all Variables 
Variable  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. T1 PDI Family/Home 
- .61 .57 .51 .31 .51 .34 .27 .14 .13 .07 .09 .16 .08 .28 .14 -.29 -.23 .05 .07 
2. T1 PDI Recreation 
  - .62 .53 .39 .39 .31 .14 .16 .11 .11 .10 .13 .03 .22 .10 -.20 -.12 -.02 .02 
3. T1 PDI Social 
    - .51 .41 .46 .37 .12 .14 .19 .14 .12 .12 .01 .23 .12 -.24 -.20 .06 .06 
4. T1 PDI 
Work/Occupational 
      - .32 .40 .28 .15 .11 .12 .27 .08 .15 .03 .25 .10 -.14 -.05 -.06 -.01 
5. T1 PDI Sexual 
        - .29 .29 .10 .11 .11 .07 .34 .09 .05 .13 -.02 -.12 -.03 -.11 -.08 
6. T1 PDI Self-Care 
          - .54 .20 .19 .21 .16 .20 .28 .13 .24 .13 -.29 -.17 -.08 -.06 
7. T1 PDI Life Support 
            - .12 .13 .15 .10 .14 .21 .27 .14 .04 -.14 -.09 -.09 -.07 
8. T2 PDI Family/Home 
              - .72 .68 .63 .45 .63 .42 .12 .24 -.15 -.17 -.06 -.02 
9. T2 PDI Recreation 
                - .72 .68 .51 .58 .35 .08 .21 -.11 -.15 -.12 -.11 
10. T2 PDI Social 
                  - .63 .52 .69 .45 .09 .29 -.14 -.16 .01 .03 
11. T2 PDI 
Work/Occupational 
                    - .40 .55 .36 .11 .20 -.10 -.09 -.05 -.05 
12. T2 PDI Sexual 
                      - .41 .26 .05 .15 -.06 -.03 -.09 -.09 
13. T2 PDI Self-Care 
                        - .62 .15 .21 -.20 -.17 -.07 -.02 
14. T2 PDI Life Support 
                          - .20 .23 -.15 -.14 .23 .24 
15.T1 UAB 
                            - .46 -.61 -.37 .21 .28 
16. T2 UAB 
                              - -.42 -.48 .40 .40 
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17. T1 Stairs Climbed 
                                - .69 -.14 -.17 
18. T2 Stairs Climbed 
                                  - -.21 -.22 
19. T1 Treadmill 
                                    - .95 
20. T2 Treadmill 
                                      - 
n 615 615 615 610 603 615 611 527 527 527 525 505 526 525 449 359 350 328 399 353 
M 6.9 7.49 6.63 7.62 6.82 4.7 4.56 3.09 3.33 2.55 3.61 2.93 1.59 1.43 5.42 1.8 51.33 73.82 0.28 0.61 
SD 1.95 2.05 2.27 2.41 3.02 2.67 2.91 2.32 2.36 2.32 2.79 2.98 2.08 2.1 2.22 1.61 25.81 26.32 1.54 3.15 
Note. T1 (Time 1); T2 (Time 2); PDI (Pain Disability Index); UAB (University of Alabama Pain Behavior Rating Scales). M 
(Mean). SD (Standard Deviation).  
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Measurement Invariance. Gender invariance testing is presented in Table 11. 
All models yielded adequate fit with a change in CFI of less than .010, which supported 
strong invariance. These results indicate that factor means and factor structures are 
similar across genders. Time invariance testing is presented in Table 12. Though the 
configural invariance model was supported by adequate fit and qualitatively similar 
factor loadings across time, the weak invariance model was rejected because it yielded a 
decrease of .021 in CFI. Modification indices in the fully constrained model indicated 
that model fit could be most improved by loading the intake UAB on intake physical 
activity (MI=46.6) and discharge UAB on discharge physical activity (MI=46.5). 
Releasing these factor loadings yielded a good fit (CFI=.96, TLI=.95, RMSEA=.043), but 
the decrease in CFI was .013. Modification indices in this model indicated that model fit 
would be further improved by loading stairs climbed at intake on physical ability at 
intake (MI=26.2) and stairs climbed at discharge on physical ability at discharge 
(MI=26.2). Releasing these factor loadings yielded a good fit (CFI=.96, TLI=.95, 
RMSEA=.040) with a .008 decrease in CFI, thus supporting partial weak invariance. 
However, strong invariance was not supported. These results indicate that the factor 
structure of the model is generally stable across time, though the factor means are 
significantly different. This result is not surprising as one would expect the mean scores 
to change as a result of treatment. 
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Table 11. Gender Invariance Testing 
Model χ
2
 df p – value 
RMSEA (95% 
CI) 
CFI TLI ∆CFI 
Configural 
Invariance 
517.19 309 <.001 .041 (.035-.047) .961 .952 - 
Men 251.86 154 <.001 .045 (.035-.055) .954 .944 .007 
Women  264.16 154 <.001 .038 (.030-.046) .966 .957 .005 
Weak 
Invariance 
535.34 325 <.001 .040 (.034-.046) .961 .954 .000 
Strong 
Invariance 
591.12 340 <.001 .043 (.037-.049) .953 .947 .008 
Note: χ
2
 (Chi-Square); df (Degrees of Freedom); RMSEA (Root Mean Square Error of Approximation); CI (Confidence 
Interval); CFI (Comparative Fit Index); TLI (Tucker Lewis Index); ∆CFI (Change in Comparative Fit Index). 
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Table 12. Latent Construct Stability across Time 
Model χ
2
 df 
p – 
value 
RMSEA (95% 
CI) 
CFI TLI ∆CFI 
Configural 
Invariance 
319.04 154 <.001 .037 (.031-.042) .968 .961 - 
Weak 
Invariance 
440.42 164 <.001 .046 (.041-.051) .947 .939 .021 
Partial Weak 
Invariance 
369.39 162 <.001 .040 (.035-.046) .960 .953 .008 
Strong 
Invariance  
6713.70 172 <.001 .218 (.214-.223) .102 .008 .866 
Note: χ
2
 (Chi-Square); df (Degrees of Freedom); RMSEA (Root Mean Square Error of Approximation); CI (Confidence 
Interval); CFI (Comparative Fit Index); TLI (Tucker Lewis Index); ∆CFI (Change in Comparative Fit Index). Partial Weak 
Invariance Model has all factors loadings constrained to be equal except stairs climbed in one minute and University of 
Alabama Pain Behavior Rating Scale.  
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 MMPI-2-RF Correlations with Outcome. Results of the correlational analyses 
were presented at the bottom of Tables 7 through 9. I applied a family-wise Bonferroni 
correction to reduce the risk of Type I error, which yielded a corrected alpha level of .025 
(.05 / 2 comparisons for each scale). Only correlations that met this alpha level were 
interpreted. Poor physical ability was positively associated with RC8 and PSYC-r, 
whereas BXD, RC4, and GIC were negatively associated with this outcome. Pain 
disability was positively associated with HLP, PSYC-r, and INTR-r. Pain disability was 
negatively associated with STW and NEGE-r.   
 
Interpretive Utility 
 
 Mean Profile Comparison. Mean profile comparisons of RC and Clinical Scale 
scores are presented by diagnostic group in figures 3 through 5. In the depressed group, 
the sample produced clinically significant (T-score > 65) mean RC Scale elevations on 
RCd, RC1, and RC2, whereas clinically significant mean elevations were observed on 
Clinical Scales 1, 2, 3, and 7. Using the traditional benchmark of five T-score points as 
the criterion for a meaningful difference (Graham, 2012), the depressed group produced 
meaningfully higher Clinical Scale scores on 1, 2, 3, 4, 6, 7, and 8. The most pronounced 
differences were observed on scale 3 (26 points higher than RC3), scale 7 (15 points), 
scale 2 (13 points), and scale 8 (13 points). However, Clinical Scales 1 and 3 were 
designed to measure psychopathology related to somatic complaints (i.e., 
Hypochondriasis and Hysteria, respectively), whereas RC3 is designed to measure one 
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unique content area of scale 3 (Cynicism) given the significant overlap between the two 
Clinical Scales. Therefore, comparisons between scale 3 and RC3 elevation rates are not 
meaningful and should be ignored. The substance use group only elevated RC Scale RC1, 
whereas Clinical Scale elevations were observed on scales 1, 2, 3, and 7. The substance 
use group had meaningfully higher Clinical Scale scores on 1, 2, 3, 4, 6, 7, 8, and 9 (i.e., 
all scales), with the most pronounced differences occurring on scales 3 (27 points higher 
than RC3), scale 7 (17 points), scale 2 (12 points), scale 1 (11 points), and scale 8 (10 
points). The no diagnosis group produced mean RC Scale elevations on RC1 and Clinical 
Scale elevations on Scales 1, 2, and 3. The no diagnosis group had meaningfully higher 
Clinical Scale scores on 1, 2, 3, 4, 6, 7, 8, and 9 (i.e., all scales). The largest differences 
occurred on scales 3 (11 points higher than RC3), scale 2 (14 points), scale 7 (14 points), 
and scale 4 (11 points). 
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EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
RC Scale Mean 65.2 71.4 65.3 49.5 48.2 53.4 55.6 52.3 45.3
Standard Deviation 11.0 11.7 10.8 10.0 7.8 11.1 11.0 10.8 8.9
Clinical Scale Mean n/a 78.5 77.9 76.4 60.9 60.8 69.1 64.8 49.9
Standard Deviation n/a 11.4 11.5 11.9 10.7 11.6 12.1 13.0 9.1
F
30
40
50
60
70
80
90
RCd RC1/S1 RC2/S2 RC3/S3 RC4/S4 RC6/S6 RC7/S7 RC8/S8 RC9/S9
Clinical Versus RC Scales: Depressed Group (N=118)
Clinical Scales
RC Scales
Figure 3. Mean Profile Comparison across RC and Clinical Scales: Depressed Group  
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Figure 4. Mean Profile Comparison across RC and Clinical Scales: Substance Use Group 
 
EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
RC Scale Mean 59.5 67.5 60.7 47.3 57.4 52.0 49.7 49.8 46.0
Standard Deviation 12.0 10.1 11.8 9.2 10.4 9.8 11.0 9.8 8.8
Clinical Scale Mean n/a 78.2 73.1 74.7 64.2 57.9 66.3 60.0 51.2
Standard Deviation n/a 11.6 12.6 10.4 8.7 9.4 12.7 12.3 8.3
F
30
40
50
60
70
80
90
RCd RC1/S1 RC2/S2 RC3/S3 RC4/S4 RC6/S6 RC7/S7 RC8/S8 RC9/S9
Clinical Versus RC Scales: Substance Use Group (N=83)
Clinical Scales
RC Scales
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Figure 5. Mean Profile Comparison across RC and Clinical Scales: No Diagnosis Group 
EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
RC Scale Mean 57.0 68.0 59.1 47.2 47.2 51.0 49.3 49.8 44.4
Standard Deviation 9.9 9.9 10.5 8.1 9.1 10.4 8.2 8.4 8.2
Clinical Scale Mean n/a 77.6 72.0 74.8 58.6 56.3 63.2 57.8 50.1
Standard Deviation n/a 10.7 12.9 11.1 11.3 11.2 11.1 10.6 9.5
F
30
40
50
60
70
80
90
RCd RC1/S1 RC2/S2 RC3/S3 RC4/S4 RC6/S6 RC7/S7 RC8/S8 RC9/S9
Clinical Versus RC Scales: No Psychiatric Diagnosis Group (N=140)
Clinical Scales
RC Scales
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 Mean profile comparisons across diagnostic groups are presented by scale set in 
figures 6 and 7. Among the Clinical Scales, statistically significant one-way ANOVA’s 
were observed for Scales 2, 4, 6, 7, and 8. The depressed group had significantly higher 
scores on scale 2 and scale 8 than the substance use and no diagnosis groups. The 
depressed group scored significantly higher than the no diagnosis group on Clinical 
Scales 6 and 7. Finally, the substance use group scored significantly higher than the no 
diagnosis group on Clinical Scale 4. For the Restructured Clinical Scales, statistically 
significant one-way ANOVA’s were observed for Scales RCd, RC1, RC2, RC4, and 
RC7. The depressed group scored significantly higher on RCd, RC1, RC2, and RC7 than 
the other groups. The substance use group scored significantly higher on RC4 compared 
to the other groups. 
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Figure 6. Mean Profile Comparison of Depressed, Substance Use, and No Diagnosis across Clinical Scales 
  
EID THD BXD RCd RC1 RC2 RC3 RC4
F(2, 340) 0.205 7.659 0.838 7.214 5.517 8.094 11.281 0.548
Significance .815 .001 .433 .001 .004 <.001 <.001 .579
Depression Mean 78.5 77.9 76.4 60.9 60.8 69.1 64.8 49.9
Standard Deviation 11.4 11.5 11.9 10.7 11.6 12.1 13.0 9.1
Substance Use Mean 78.2 73.1 74.7 64.2 57.9 66.3 60.0 51.2
Standard Deviation 11.6 12.6 10.4 8.7 9.4 12.7 12.3 8.3
No Diagnosis Mean 77.6 72.0 74.8 58.6 56.3 63.2 57.8 50.1
Standard Deviation 10.7 12.9 11.1 11.3 11.2 11.1 10.6 9.5
F
30
40
50
60
70
80
90
S1 S2 S3 S4 S6 S7 S8 S9
Clinical Scales (N=341)
Substance Use (n=83)
Depression (n=118)
No Diagnosis (n=140)
a
a
a a
b
b
a
a
a
ab
a
b
b
ab
a
b
ab
a
a
b
b
a
a
a
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Figure 7. Mean Profile Comparison of Depressed, Substance Use, and No Diagnosis across Restructured Clinical Scales 
 
EID THD BXD RCd RC1 RC2 RC3 RC4 RC6
F(2, 340) 18.734 4.458 10.470 2.341 37.107 1.672 14.997 2.553 1.005
Significance <.001 .012 <.001 .098 <.001 .189 <.001 .079 .367
Depression Mean 65.2 71.4 65.3 49.5 48.2 53.4 55.6 52.3 45.3
Standard Deviation 11.0 11.7 10.8 10.0 7.8 11.1 11.0 10.8 8.9
Substance Use Mean 59.5 67.5 60.7 47.3 57.4 52.0 49.7 49.8 46.0
Standard Deviation 12.0 10.1 11.8 9.2 10.4 9.8 11.0 9.8 8.8
No Diagnosis Mean 57.0 68.0 59.1 47.2 47.2 51.0 49.3 49.8 44.4
Standard Deviation 9.9 9.9 10.5 8.1 9.1 10.4 8.2 8.4 8.2
F
30
40
50
60
70
80
90
RCd RC1 RC2 RC3 RC4 RC6 RC7 RC8 9
RC Scales (N=341)
Substance Use (n=83)
Depression (n=118)
No Diagnosis (n=140)
b
a
a a
a
b b
a
a
a
a
a
a
b
a
a
a
a
b
a
a
a
a
a
a
a
a
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Elevation Rate Comparison. In order to facilitate interpretation, elevation rates 
at 65T and 80T are described in the text, but elevation rate comparisons for 60T through 
90T are presented in Table 13. T-score levels of 65 and 80 were chosen because they 
represent the standard interpretive cutoff and three standard deviations above the 
population mean, respectively, thus facilitating an investigation of elevation rate 
differences at the standard and high ends. RCd demonstrated elevation rates ranging from 
25 (no diagnosis) to 58 percent (depression) at a cutoff of 65T. RCd elevation rates 
ranged from 0 (no diagnosis) to 7 percent (substance use) at a cutoff of 80T.  
 At a cutoff of 65T, RC1 elevation rates ranged from 57 (substance use) to 73 
percent (depression), all of which were significantly lower than Clinical Scale 1 elevation 
rates which ranged from 87 (depression) to 90 percent (no diagnosis). Considering a 
cutoff of 80T, RC1 scale elevation rates ranged from 12 (substance use) to 24 percent 
(depression). These rates were significantly lower than Clinical Scale 1 rates, which 
ranged from 41 (no diagnosis) to 51 percent (depression).  
 Restructured Clinical Scale RC2 had 65T elevation rates ranging from 33 (no 
diagnosis) to 53 percent (depression), all of which were lower than Clinical Scale 2 
elevation rates. Scale 2 ranged from 67 (no diagnosis) to 86 percent (depression). 
Similarly, at a T-score cutoff of 80T RC2 produced lower elevation rates than Clinical 
Scale 1 in all groups. RC2 elevation rates ranged from 6 (no diagnosis) to 13 percent 
(depression), whereas scale 2 elevation rates ranged from 31 (no diagnosis) to 47 percent 
(depression).  
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 At a cutoff of 65T, RC3 elevation rates ranged from 4 (no diagnosis) to 10 percent 
(substance use), whereas Clinical Scale elevation rates were significantly higher and 
ranged from 84 (no diagnosis) to 87 percent (depression). Considering a T-score cutoff of 
80T, RC3 elevation rates ranged from 0 (no diagnosis and substance use) to 1 percent 
(depression), and scale 3 elevation rates ranged from 28 (substance use) to 39 percent 
(depression). However, RC3 was only significantly less than scale 3 in the depressed 
group because confidence intervals could not be computed for a value of zero.  
 Restructured Clinical Scale RC4 had 65T elevation rates that ranged from 3 
(depression) to 23 percent, all of which were significantly higher than the Clinical Scale 4 
rates, which ranged from 29 (no diagnosis) to 55 percent (substance use). Considering a 
cutoff of 80T, RC4 elevation rates ranged from 0 (no diagnosis and depression) to 2 
(substance use). Scale 4 elevation rates in the depressed, substance use, and no diagnosis 
group approximated 4 percent. No significant differences were observed. 
 Considering a cutoff of 65T, RC6 elevation rates ranged from 10 (substance use) 
to 15 percent (depression), whereas Clinical Scale 6 elevation rates ranged from 21 (no 
diagnosis) to 39 percent (depression). RC6 elevation rates were significantly lower than 
scale 6 elevations in the depressed group. At a cutoff of 80T, RC6 elevation rates ranged 
from 1 (no diagnosis) to 3 percent (depression), and scale 6 elevation rates ranged from 1 
(substance use) to 5 percent (depression). No significant differences were observed. 
 Restructured Clinical Scale RC7 had elevation rates at a cutoff of 65T that ranged 
from 4 (no diagnosis) to 22 percent (depression). Clinical Scale 7 elevation rates at that 
cutoff ranged from 41 (no diagnosis) to 62 percent (depression), all of which were 
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significantly higher than the RC7 elevation rates. At a cutoff of 80T, RC7 elevation rates 
ranged from 0 (no diagnosis) to 3 percent (depression). Clinical Scale 7 elevation rates 
ranged from 19 (no diagnosis) to 25 percent (depression). RC7 elevation rates were 
significant lower than scale 7 elevation rates in the substance use and depression groups, 
and confidence intervals could not be computed for RC7 in the no diagnosis group.  
 Restructured Clinical Scale RC8 had 65T elevation rates ranging from 6 (no 
diagnosis) to 13 percent (depression). Clinical Scale 8 elevation rates ranged from 26 (no 
diagnosis) to 53 percent (depression), all of which were significantly higher than RC8’s 
elevation rates. Considering a cutoff of 80T, RC8 elevation rates ranged from 0 (no 
diagnosis and substance use) to 3 percent (depression), whereas scale 8 elevation rates 
ranged from 3 (no diagnosis) to 13 percent (depression). The RC8 elevation rate was 
significantly lower than scale 8 elevation rate in the depression group, and confidence 
intervals could not be computed for RC8 in the no diagnosis group and substance use 
group. 
 At a cutoff of 65T, RC9 elevation rates ranged from 1 (no diagnosis) to 4 percent 
(depression), whereas scale 9 rates ranged from 4 (substance use) to 9 percent (no 
diagnosis). Elevation rates for RC9 in the no diagnosis group were significantly lower 
than scale 9 elevation rates. In all groups, both RC9 and scale 9 had no elevations at a T-
score cutoff of 80T. 
 Restructured Clinical Scale RCd had a significantly higher 65T elevation rate in 
the depressed group compared to the no diagnosis and substance use groups. No 
significant differences were observed for a cutoff of 80T, though a confidence interval for 
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the no diagnosis group elevation rate could not be computed. The RC and Clinical Scales 
demonstrated similar patterns of discrimination across the three groups on RC1/S1 (65T 
and 80T), RC2/S2 (65T), RC3/S3 (65T and 80T), RC4/S4 (80T), RC6/S6 (80T), RC7/S7 
(65T), RC8/S8 (80T), and RC9/S9 (65 and 80T). For example, using a T-score cutoff of 
65, the three groups RC1 elevation rates ranged from 57 (substance use) to 73 percent 
(depression), with no significant differences. Likewise, the three groups scale 1 elevation 
rates ranged from 87 (depression) to 90 percent (no diagnosis), also with no significant 
differences. However, there were a meaningful number of comparisons where the 
discriminant characteristics of the RC and Clinical Scales differed.  
 The 80T RC2 elevation rate in the depressed group was significantly higher than 
the other groups, whereas the groups did not significantly differ on Scale 2. At a cutoff of 
65T, RC4 elevation rates were significantly higher in the substance use group compared 
to the depression and no diagnosis groups. The substance use and depression group did 
not differ on Scale 4 elevation rates, though both had significantly higher rates than the 
no diagnosis group. Whereas RC6 did not differ across groups on 65T elevation rates, 
scale 6 elevation rates were significantly higher in the depressed group than the no 
diagnosis group. Considering a cutoff of 80T, RC7 elevation rates did not meaningfully 
differ across groups, whereas scale 7 elevation rates were significantly higher in the 
depressed group compared to the no diagnosis group. The RC8 elevation rates using a 
cutoff of 65T did not significantly differ across diagnostic groups, whereas the depression 
group had a significantly higher scale 8 elevation rate than the no diagnosis group.  
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Table 13. Elevation Rates at Various Cutoffs for the Clinical and Restructured Clinical Scales 
Cutoff Scale 
Substance Use (n=83) Depression (n=118) No Diagnosis (n=140) 
Rate 95% CI Rate 95% CI Rate 95% CI 
60 RCd 43.4a 32.7 – 54.0 68.6b 60.3 – 77.0 35.0a 27.1 - 42.9 
65 RCd 28.9a 19.2 - 38.7 57.6b 48.7 - 66.5 25.0a 17.8 - 32.2 
70 RCd 18.1ab 9.8 - 26.4 34.7b 26.2 - 43.3 14.3a 8.5 - 20.1 
75 RCd 13.3ab 6.0 - 20.5 22.9b 15.3 - 30.5 5.0a 1.4 - 8.6 
80 RCd 7.2a 1.7 - 12.8 6.8a 2.2 - 11.3 0.0 n/a 
85 RCd 2.4a 0.0 - 5.7 0.8a 0.0 - 2.5 0.0 n/a 
90 RCd 0.0 n/a 0.0 n/a 0.0 n/a 
        
60 RC1 75.9a 66.7 - 85.1 81.4a 74.3 - 88.4 83.6a 77.4 - 89.7 
 S1 95.2a 90.6 - 99.8 94.1a 89.8 - 98.3 97.1a 94.4 - 99.9 
65 RC1 56.6a 46.0 - 67.3 72.9a 64.9 - 80.9 62.1a 54.1 - 70.2 
 S1 88.0a 80.9 - 95.0 87.3a 81.3 - 93.3 90.0a 85.0 - 95.0 
70 RC1 43.4a 32.7 - 54.0 55.1a 46.1 - 64.1 41.4a 33.3 - 49.6 
 S1 77.1a 68.1 - 86.1 77.1a 69.5 - 84.7 75.0a 67.8 - 82.2 
75 RC1 21.7a 12.8 - 30.6 37.3a 28.6 - 46.0 20.7a 14.0 - 27.4 
 S1 59.0a 48.5 - 69.6 66.1a 57.6 - 74.6 56.4a 48.2 - 64.6 
80 RC1 12.0a 5.0 - 19.1 23.7a 16.1 - 31.4 13.6a 7.9 - 19.2 
 S1 41.0a 30.4 - 51.5 50.8a 41.8 - 59.9 40.7a 32.6 - 48.9 
85 RC1 6.0a 0.9 - 11.1 11.9a 6.0 - 17.7 7.1a 2.9 - 11.4 
 S1 26.5a 17.0 - 36.0 31.4a 23.0 - 39.7 28.6a 21.1 - 36.1 
90 RC1 3.6a 0.0 - 7.6 5.1a 1.1 - 9.0 2.9a 0.1 - 5.6 
 S1 18.1a 9.8 - 26.4 21.2a 13.8 - 28.6 15.0a 9.1 - 20.9 
        
60 RC2 51.8ab 41.1 - 62.6 70.3a 62.1 - 78.6 45.0b 36.8 - 53.2 
 S2 85.5ab 78.0 - 93.1 94.1a 89.8 - 98.3 82.1b 75.8 - 88.5 
65 RC2 37.3ab 26.9 - 47.8 52.5a 43.5 - 61.6 32.9b 25.1 - 40.6 
 S2 73.5ab 64.0 - 83.0 86.4a 80.3 - 92.6 67.1b 59.4 - 74.9 
  
89 
 
Cutoff Scale 
Substance Use (n=83) Depression (n=118) No Diagnosis (n=140) 
Rate 95% CI Rate 95% CI Rate 95% CI 
70 RC2 16.9a 8.8 - 24.9 28.0a 19.9 - 36.1 14.3a 8.5 - 20.1 
 S2 55.4a 44.7 - 66.1 75.4b 67.7 - 83.2 56.4a 48.2 - 64.6 
75 RC2 10.8a 4.2 - 17.5 18.6a 11.6 - 25.7 7.9a 3.4 - 12.3 
 S2 41.0ab 30.4 - 51.5 62.7b 54.0 - 71.4 39.3a 31.2 - 47.4 
80 RC2 7.2a 1.7 - 12.8 12.7b 6.7 - 18.7 6.4a 2.4 - 10.5 
 S2 31.3a 21.3 - 41.3 46.6a 37.6 - 55.6 30.7a 23.1 - 38.4 
85 RC2 4.8a 0.2 - 9.4 2.5a 0.0 - 5.4 0.7a 0.7 - 2.1 
 S2 16.9a 8.8 - 24.9 31.4a 23.0 - 39.7 17.9a 11.5 - 24.2 
90 RC2 3.6a 0.0 - 7.6 1.7a 0.0 - 4.0 0.7a 0.7 - 2.1 
 S2 10.8a 4.2 - 17.5 16.9a 10.2 - 23.7 13.6a 7.9 - 19.2 
        
60 RC3 9.6a 3.3 - 16.0 19.5a 12.3 - 26.6 10.7a 5.6 - 15.8 
 S3 91.6a 85.6 - 97.5 91.5a 86.5 - 96.6 91.4a 86.8 - 96.1 
65 RC3 9.6a 3.3 - 16.0 8.5a 3.4 - 13.5 4.3a 0.9 - 7.6 
 S3 85.5a 78 - 93.1 86.4a 80.3 - 92.6 83.6a 77.4 - 89.7 
70 RC3 6.0a 0.9 - 11.1 4.2a 0.6 - 7.9 2.1a 0.3 - 4.5 
 S3 71.1 61.3 - 80.8 73.7 65.8 - 81.7 65.0 57.1 - 72.9 
75 RC3 1.2a 0.0 - 3.6 1.7a 0.0 - 4.0 0.0 n/a 
 S3 49.4a 38.6 - 60.2 57.6a 48.7 - 66.5 50.7a 42.4 - 59.0 
80 RC3 0.0 n/a 0.8 0.0 - 2.5 0.0 n/a 
 S3 27.7a 18.1 - 37.3 39.0a 30.2 - 47.8 32.9a 25.1 - 40.6 
85 RC3 0.0 n/a 0.0 n/a 0.0 n/a 
 S3 18.1a 9.8 - 26.4 23.7a 16.1 - 31.4 18.6a 12.1 - 25.0 
90 RC3 0.0 n/a 0.0 n/a 0.0 n/a 
 S3 10.8 4.2 - 17.5 14.4 8.1 - 20.7 10.0 5.0 - 15.0 
        
60 RC4 30.1a 20.3 - 40.0 7.6b 2.8 - 12.4 10.7b 5.6 - 15.8 
 S4 69.9a 60.0 - 79.7 52.5a 43.5 - 61.6 43.6b 35.4 - 51.8 
65 RC4 22.9a 13.9 - 31.9 3.4b 0.1 - 6.7 5.0b 1.4 - 8.6 
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Cutoff Scale 
Substance Use (n=83) Depression (n=118) No Diagnosis (n=140) 
Rate 95% CI Rate 95% CI Rate 95% CI 
 S4 55.4a 44.7 - 66.1 36.4a 27.8 - 45.1 28.6b 21.1 - 36.1 
70 RC4 13.3a 6.0 - 20.5 0.8b 0.8 - 2.5 0.7b 0.0 - 2.1 
 S4 27.7a 18.1 - 37.3 22.0a 14.6 - 29.5 16.4a 10.3 - 22.6 
75 RC4 7.2a 1.7 - 12.8 0.0 n/a 0.7b 0.0 - 2.1 
 S4 8.4a 2.5 - 14.4 10.2a 4.7 - 15.6 9.3a 4.5 - 14.1 
80 RC4 2.4 0.0 - 5.7 0.0 n/a 0.0 n/a 
 S4 3.6a 0.0 - 7.6 4.2a 0.6 - 7.9 4.3a 0.9 - 7.6 
85 RC4 1.2 0.0 - 3.6 0.0 n/a 0.0 n/a 
 S4 0.0 n/a 3.4a 0.1 - 6.7 2.1a 0.3 - 4.5 
90 RC4 0.0 n/a 0.0 n/a 0.0 n/a 
 S4 0.0 n/a 0.0 n/a 0.7 0.0 - 2.1 
        
60 RC6 28.9a 19.2 - 38.7 30.5a 22.2 - 38.8 24.3a 17.2 - 31.4 
 S6 42.2a 31.5 - 52.8 50.0a 41.0 - 59.0 34.3a 26.4 - 42.1 
65 RC6 9.6a 3.3 - 16.0 15.3a 8.8 - 21.7 13.6a 7.9 - 19.2 
 S6 22.9ab 13.9 - 31.9 39.0b 30.2 - 47.8 21.4a 14.6 - 28.2 
70 RC6 3.6a 0.0 - 7.6 5.9a 1.7 - 10.2 6.4a 2.4 - 10.5 
 S6 9.6a 3.3 - 16.0 17.8a 10.9 - 24.7 11.4a 6.2 - 16.7 
75 RC6 2.4a 0.0 - 5.7 3.4a 0.1 - 6.7 3.6a 0.5 - 6.6 
 S6 3.6a 0.0 - 7.6 12.7a 6.7 - 18.7 5.0a 1.4 - 8.6 
80 RC6 1.2a 0.0 - 3.6 3.4a 0.1 - 6.7 0.7a 0.7 - 2.1 
 S6 1.2a 0.0 - 3.6 5.1a 1.1 - 9.0 2.1a 0.3 - 4.5 
85 RC6 0.0 n/a 0.8a 0.0 - 2.5 0.7a 0.7 - 2.1 
 S6 0.0 n/a 3.4a 0.1 - 6.7 2.1a 0.3 - 4.5 
90 RC6 0.0 n/a 0.8 0.0 - 2.5 0.0 n/a 
 S6 0.0 n/a 0.0 n/a 0.7 0.7 - 2.1 
        
60 RC7 19.3a 10.8 - 27.8 33.9a 25.4 - 42.4 13.6b 7.9 - 19.2 
 S7 66.3a 56.1 - 76.4 72.9a 64.9 - 80.9 62.9a 54.9 - 70.9 
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Cutoff Scale 
Substance Use (n=83) Depression (n=118) No Diagnosis (n=140) 
Rate 95% CI Rate 95% CI Rate 95% CI 
65 RC7 13.3ab 6.0 - 20.5 22.0a 14.6 - 29.5 3.6b 0.5 - 6.6 
 S7 44.6ab 33.9 - 55.3 61.9a 53.1 - 70.6 40.7b 32.6 - 48.9 
70 RC7 6.0a 0.9 - 11.1 15.3a 8.8 - 21.7 1.4b 0.5 - 3.4 
 S7 38.6ab 28.1 - 49.0 55.1b 46.1 - 64.1 30.7a 23.1 - 38.4 
75 RC7 3.6ab 0.0 - 7.6 7.6b 2.8 - 12.4 0.7a 0.7 - 2.1 
 S7 21.7ab 12.8 - 30.6 35.6b 27.0 - 44.2 12.1a 6.7 - 17.6 
80 RC7 1.2a 0.0 - 3.6 2.5a 0.3 - 5.4 0.0 n/a 
 S7 19.3ab 10.8 - 27.8 24.6b 16.8 - 32.3 10.0a 5.0 - 15.0 
85 RC7 0.0 n/a 0.0 n/a 0.0 n/a 
 S7 10.8 4.2 - 17.5 10.2 4.7 - 15.6 4.3 0.9 - 7.6 
90 RC7 0.0 n/a 0.0 n/a 0.0 n/a 
 S7 6.0a 0.9 - 11.1 4.2a 0.6 - 7.9 2.1a 0.3 - 4.5 
        
60 RC8 14.5a 6.9 - 22.0 19.5a 12.3 - 26.6 8.6a 3.9 - 13.2 
 S8 47.0ab 36.3 - 57.7 63.6b 54.9 - 72.2 38.6a 30.5 - 46.6 
65 RC8 7.2a 1.7 - 12.8 12.7a 6.7 - 18.7 5.7a 1.9 - 9.6 
 S8 36.1ab 25.8 - 46.5 52.5b 43.5 - 61.6 25.7a 18.5 - 33.0 
70 RC8 4.8ab 0.2 - 9.4 8.5b 3.4 - 13.5 0.7a 0.0 - 2.1 
 S8 22.9ab 13.9 - 31.9 39.8b 31.0 - 48.7 15.7a 9.7 - 21.7 
75 RC8 0.0 n/a 3.4 0.1 - 6.7 0.0 n/a 
 S8 13.3ab 6.0 - 20.5 22.0a 14.6 - 29.5 8.6b 3.9 - 13.2 
80 RC8 0.0 n/a 2.5 0.3 - 5.4 0.0 n/a 
 S8 7.2ab 1.7 - 12.8 12.7b 6.7 - 18.7 2.9a 0.1 - 5.6 
85 RC8 0.0 n/a 0.0 n/a 0.0 n/a 
 S8 2.4a 0.0 - 5.7 8.5a 3.4 - 13.5 1.4a 0.5 - 3.4 
90 RC8 0.0 n/a 0.0 n/a 0.0 n/a 
 S8 0.0 n/a 4.2 0.6 - 7.9 0.0 n/a 
        
60 RC9 7.2a 1.7 - 12.8 6.8a 2.2 - 11.3 6.4a 2.4 - 10.5 
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Cutoff Scale 
Substance Use (n=83) Depression (n=118) No Diagnosis (n=140) 
Rate 95% CI Rate 95% CI Rate 95% CI 
 S9 15.7a 7.8 - 23.5 11.9a 6.0 - 17.7 14.3a 8.5 - 20.1 
65 RC9 3.6a 0.0 - 7.6 4.2a 0.6 - 7.9 1.4a 0.5 - 3.4 
 S9 3.6a 0.0 - 7.6 7.6a 2.8 - 12.4 8.6a 3.9 - 13.2 
70 RC9 1.2a 0.0 - 3.6 2.5a 0.3 - 5.4 0.0 n/a 
 S9 0.0 n/a 2.5a 0.3 - 5.4 3.6a 0.5 - 6.6 
75 RC9 0.0 n/a 0.0 n/a 0.0 n/a 
 S9 0.0 n/a 0.0 n/a 0.7 0.7 - 2.1 
80 RC9 0.0 n/a 0.0 n/a 0.0 n/a 
 S9 0.0 n/a 0.0 n/a 0.0 n/a 
85 RC9 0.0 n/a 0.0 n/a 0.0 n/a 
 S9 0.0 n/a 0.0 n/a 0.0 n/a 
90 RC9 0.0 n/a 0.0 n/a 0.0 n/a 
 S9 0.0 n/a 0.0 n/a 0.0 n/a 
Note. Scales with different subtexts are significantly different (Tukey). Bolded and underlined RC Scale elevation rates are 
significantly lower than corresponding Clinical Scale elevation rate. n/a (not applicable). CI (Confidence Interval). RCd 
(Demoralization). RC1 (Somatic Complaints). S1 (Hypochondriasis). RC2 (Low Positive Emotions). S2 (Depression). RC3 
(Cynicism). S3 (Hysteria). RC4 (Antisocial Behavior). S4 (Psychopathic Deviate). RC6 (Persecutory Ideation). S6 (Paranoia). 
RC7 (Dysfunctional Negative Emotions). S7 (Psychastenia). RC8 (Aberrant Experiences). S8 (Schizophrenia). RC9 
(Hypomanic Activation). S9 (Hypomania).  
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DISCUSSION 
 
 Research on use of the MMPI-2-RF among chronic low back pain patients is 
lacking. In this study, descriptive statistics, reliability information, convergent validity 
correlations, treatment outcome associations, and interpretive utility comparisons were 
provided to assess and guide use of the MMPI-2-RF in this setting.  
 
Psychometrics 
 Though descriptive findings generally indicated similar scores across genders, 
men scored meaningfully higher than women on BXD, RC4, JCP, SUB, MEC, AGGR-r, 
and DISC-r, and women scored meaningfully higher on Fs, FBS-r, GIC, MSF, and AES. 
The results for men are not surprising, as they have typically exhibited higher 
externalizing scale scores than women in a variety of samples, including the normative 
sample (Tellegen & Ben-Porath, 2008/2011). The Interest Scale score differences (i.e., 
MEC and AES) are also typical, as these scales were generated from Clinical Scale 5 
(Masculinity-Feminitiy; Ben-Porath, 2012). The findings that women score higher on 
Symptom Validity (FBS-r) and Multiple Specific Fears (MSF) is consistent with findings 
in the normative sample and past research in other medical populations (Tarescavage et 
al., 2013). However, findings that women score meaningfully higher on Infrequent 
Somatic Complaints (Fs) and Gastrointestinal Complaints (GIC) are less typical, though 
this pattern is more common in settings with higher rates of psychopathology (e.g., 
community mental health center outpatients). Though this is a medical sample, it has 
similar levels of mood pathology, which may account for these differences. Taken as a 
  
94 
 
whole, the descriptive analyses indicate that men present with more externalizing 
behaviors than women in a chronic pain setting, and patients overall present with 
substantial levels of emotional and somatic problems on the MMPI-2-RF, which is 
consistent with the literature reviewed in the introduction (Von Korff et al., 2005). 
 As expected, internal consistency estimates in this sample were generally in line 
with the normative sample, although Specific Problems scale Malaise had a meaningfully 
lower internal consistency estimate (.47 versus .62). Interestingly, when considering 
mean inter-item correlations, which some have argued are more appropriate for shorter 
scales such as the Specific Problem Scales (Briggs & Cheek, 1986), the reliability of the 
Malaise scale was also worse than the normative sample. Head Pain Complaints also 
showed a lower mean inter-item correlation, though the rest of the test’s substantive 
scales were generally consistent with the normative sample using this metric. However, 
standard error of measurement information is of more practical utility than these 
estimates, because it can be used to evaluate observed scale scores in the context of true 
score estimates and confidence intervals that take into account a scale’s reliability and 
variability (Groth-Marnat, 2009). Considering this aspect of reliability, most of the 
MMPI-2-RF’s substantive scales had similar estimates to the normative sample, except 
for Gastrointestinal Complaints, Cognitive Complaints, Suicidal Ideation, and Anxiety. 
Despite improved reliability in terms of internal consistency and mean inter-item 
correlations, these scales had substantially higher variance than the normative sample, 
which accounts for these differences in standard errors of measurement. This increased 
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variance is unsurprising given the higher base rates of health problems as well as mood 
and anxiety disorders in this population (Von Korff et al., 2005).  
 As hypothesized, scales in the Emotional Dysfunction domain demonstrated 
convergent correlations with mental health history information, including psychotropic 
medication use and mental health diagnoses. Scales measuring constructs relevant to 
anxiety were associated with benzodiazepine use, whereas measures of both constructs 
relevant to depression and anxiety were associated with antidepressant use. Interestingly, 
Stress/Worry (STW), Anxiety (AXY), and Neuroticism (NEGE-r) were associated with 
antipsychotic medication use. These findings might have been observed because 
individuals were prescribed atypical anti-psychotics for the management of mood 
disorders (e.g., Abilify and Seroquel). Almost all of the MMPI-2-RF’s Emotional 
Dysfunction scales were associated with major depressive disorder, with Higher Order 
scale Emotional/Internalizing Dysfunction (EID) and Restructured Clinical Scale 
Demoralization (RCd) demonstrating the strongest correlations. These findings indicate 
that nearly all of the Emotional Dysfunction scales are relevant to major depressive 
disorder symptoms in this setting, but the disorder is best characterized by more general 
mood dysfunction and demoralization. Restructured Clinical Scale Dysfunctional 
Negative Emotions (RC7) and Specific Problem Scale Anxiety (AXY) were associated 
with a bipolar disorder diagnosis, indicating that these scales might be relevant to 
consider in addition to the externalizing scales, which showed the strongest associations 
with this diagnosis.  Not surprisingly,RC7 and AXY were also associated with anxiety 
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disorders, and AXY was associated with post-traumatic stress disorder diagnosis, a 
finding that has been demonstrated in past research (Arbisi et al., 2011).  
Also as hypothesized, the Emotional Dysfunction scales demonstrated a number 
of convergent associations with the PDI and the DASS. The PDI findings are consistent 
with the bio-psychosocial model of pain, which postulates that the experience of pain is 
moderated by emotions. The Emotional Dysfunction scales mostly correlated with the 
DASS Depression, Stress, and Anxiety scales in expected ways, though some exceptions 
occurred. Most notably, Demoralization (RCd) demonstrated its highest association with 
DASS Depression, not the DASS Stress, a scale whose development was analogous to 
RCd in that the test authors isolated items measuring a shared (but unique) construct 
associated with anxiety and depression (Lovibond & Lovibond, 1995). The DASS Stress 
scale was characterized by associations with Dysfunctional Negative Emotions (RC7) 
and Neuroticism (NEGE-r) in this sample. These findings highlight the difference 
between the DASS Stress and RCd scales, as Lovibond and Lovibond (1995) described 
the Stress scale as containing items “referring to difficulty relaxing, nervous tension, 
irritability, and agitation” (p. 336). This is in contrast to the demoralization items that 
measure general unhappiness and dissatisfaction.  
As hypothesized, the Thought Dysfunction scales were associated with post-
traumatic stress disorder diagnosis and the PDI self-care and life support scales. The 
former finding is consistent with past research demonstrating that individuals with post-
traumatic stress disorder score higher on these scales than controls (Arbisi et al., 2011), 
likely because of potential re-experiencing symptoms, hyperarousal, and distorted 
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negative worldviews. Additionally, findings from the MMPI-2-RF Technical Manual 
indicate that RC8 is associated with dissociation in civil disability samples (Tellegen & 
Ben-Porath, 2008/2011). Contrary to expectations, Thought Dysfunction as measured by 
the MMPI-2-RF was not associated with antipsychotic medication use. The base rate of 
psychotic symptoms in this sample may have been too low to detect a correlation, or it 
may be that antipsychotic medications suppressed psychotic symptoms. Interestingly, 
most Thought Dysfunction scales were associated with a diagnosis of somatoform 
disorder, and Somatic Complaints (RC1) was the only other MMPI-2-RF scale 
demonstrating a significant correlation with somatoform disorder in this study. This 
finding is consistent with the bio-psychosocial model of pain, which postulates that the 
experience of pain is moderated by cognitive factors, and it suggests that moderate 
elevations on the Thought Dysfunction scales in chronic pain patients may reflect 
cognitive distortions rather than psychotic symptoms.  
Consistent with hypotheses, scales in the Externalizing domain were associated 
with substance use and smoking. However, these scale scores were uncorrelated with 
narcotic pain medication usage. This sample may have been less medication-seeking, 
perhaps because of the pain center’s screening process, or the MMPI-2-RF’s 
externalizing scales may not be as sensitive to this form of substance abuse. However, 
past research with the MMPI-2-RF in spine surgery candidates indicates that these scales 
are sensitive to opioid abuse concerns (Block et al., 2013). Scales in the externalizing 
domain were negatively associated with pain disability and poor physical ability. Indeed, 
the opposite effect seems more likely, such that antisociality and associated constructs 
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should be positively associated to these constructs, because antisocial individuals may be 
noncompliant with medical recommendations. These findings may be an artifact of 
gender differences, as men score much higher than women on the externalizing scales 
and have slightly less pain disability/physical ability problems.  
Scores from the Somatic/Cognitive domain demonstrated several convergent 
associations with criteria as expected. These findings included associations with self-
reported and observed pain, hours resting per day, pain disability, and medication use. 
However, the scales were generally uncorrelated with observed physical ability. This 
finding demonstrates that self-reported pain complaints and actual physical functioning 
may not converge, because the former is influenced by a variety of mood and cognitive 
factors (Gatchel, 2004; Gatchel et al., 2007). Contrary to expectations, scales in the 
Interpersonal Functioning domain were generally uncorrelated with criteria. It was 
expected that these scales would be correlated with pain disability, especially in the 
Family/Home, Social, Recreation, and Sexual domains. Future research on these scales is 
needed before they are used to infer implications specific to chronic back pain patients.  
Results of the treatment outcome analyses partially supported the hypotheses, 
which were formulated based on the bio-psychosocial model of pain. Specifically, it was 
hypothesized that scales from the Internalizing, Thought Dysfunction, and Interpersonal 
Functioning Domains would be associated with poor physical ability and disability 
outcomes after treatment. The Thought Dysfunction domain had the most robust findings, 
as its constructs were positively associated with poor outcome in terms of physical ability 
and pain disability. Although Internalizing Scales associated with depression were 
  
99 
 
positively associated with pain disability, PSY-5 scale Neuroticism (NEGE-r) and 
Specific Problems Scale Stress/Worry (STW) were associated with better physical ability 
outcomes. It is important to note that descriptive findings in the current study indicated 
that though the patients demonstrated meaningfully higher STW and NEGE-r scores than 
the general population, their mean scores did not reach clinically significant levels (i.e., 
65T or higher). Consequently, these findings indicate that individuals with moderate 
levels of neuroticism and worry are likely to have improved treatment outcomes. 
Additionally, the PSY-5 NEGE-r scale measures a dysfunctional personality trait 
characterized by anxiety, insecurity, worry, and fear, whereas the STW Specific 
Problems scale primarily measures worrying related to preoccupation with 
disappointments. For these reasons, the more specific STW scale can be used to refine 
interpretation of the broader NEGE-r scale. Indeed, six of the seven STW items are 
scored on NEGE-r. In light of these considerations, the findings indicate that the 
dysfunctional personality trait of neuroticism in general and worry about disappointing 
others in particular are associated with better physical outcomes. Perhaps these findings 
were observed because individuals with moderate levels of neuroticism were more likely 
to comply with treatment due to worries of disappointing themselves and/or others, thus 
leading to improved treatment outcomes. However, the findings may differ in samples 
with more severe levels of neuroticism, which may become debilitating. Therefore, more 
research into these associations is needed before implementing them into practice.  
The reason why some Externalizing Scales were associated with better physical 
ability outcomes is unclear. Whereas the most likely explanation for similar concurrent 
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findings was a statistical artifact caused by gender differences on the criteria, this 
structural model demonstrated strong gender measurement invariance, indicating that the 
criteria’s factor loadings and means were not significantly different across genders. One 
alternative explanation for these findings is that individuals with externalizing behaviors 
were identified and placed in the treatment program’s chemical dependency track which 
provided more focused interventions that may have led to relatively greater improvement 
in these individuals compared to those placed in the general treatment program. However, 
data are not available to test this explanation empirically. More research is needed with 
the MMPI-2-RF in this setting to identify whether these findings replicate, as they do not 
converge with predominant theories and may be sample specific.  
 
Clinical Interpretation 
Overall, the results of the correlational analyses indicate that the MMPI-2-RF’s 
scales are associated with a number of constructs relevant for the assessment of chronic 
back pain patients, though future research is needed for the Interpersonal Functioning and 
Externalizing domains in particular. Some of the most promising findings are those 
indicating that scales measuring constructs associated with thought dysfunction and 
depression are correlated with poor outcome, whereas moderate levels of anxiety 
(particularly neuroticism) are correlated with better outcome. In order to facilitate 
practitioner interpretation of the correlate findings, they are summarized in Table 14 and 
correlates that are particularly strong and/or salient in a chronic pain setting are discussed 
in Table 15 in the context of the standard interpretive guidelines outlined by Ben-Porath 
and Tellegen (2008/2011). 
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Table 14. List of interpreted MMPI-2-RF correlates 
Scale  Correlates 
Higher-Order   
Emotional/Internalizing Dysfunction 
(EID) 
 Number of Antidepressants; Hours Resting per Day; Major Depressive 
Disorder; PDI Total Score; Duration of pain; DASS Depression; DASS 
Anxiety; DASS Stress 
 
Thought Dysfunction (THD)  Major Depressive Disorder; Somatoform Disorder; Bipolar Disorder; Post-
Traumatic Stress Disorder; DASS Depression; DASS Anxiety; DASS Stress 
 
Behavioral/Externalizing Dysfunction 
(BXD) 
 Poor Physical Ability (-); Current Smoker; Substance Use; Bipolar Disorder; 
Post-Traumatic Stress Disorder; PDI Family/Home 
Restructured Clinical   
Demoralization (RCd)  Number of Antidepressants; Hours Resting per Day; Substance Use; Major 
Depressive Disorder; PDI Total Score; DASS Depression; DASS Anxiety; 
DASS Stress 
Somatic Complaints (RC1)  Pain Intensity Rating; Number of Antidepressants; Number of 
Benzodiazepines; Hours Resting per Day; Major Depressive Disorder; 
Somatoform Disorder; PDI Total Score; PDI Family/Home; PDI Socialization; 
PDI Sexual; PDI Self-Care; PDI Life Support; DASS Depression; DASS 
Anxiety; DASS Stress 
Low Positive Emotions (RC2)  Hours Resting per Day; Major Depressive Disorder; PDI Total Score; PDI 
Socialization; PDI Occupation; DASS Depression; DASS Stress 
Cynicism (RC3)  Bipolar Disorder; DASS Depression; DASS Stress 
Antisocial Behavior (RC4)  Poor Physical Ability (-); Current Smoker; Substance Use; Bipolar Disorder; 
Post-Traumatic Stress Disorder 
Persecutory Ideation (RC6)  Bipolar Disorder; Post-Traumatic Stress Disorder; DASS Depression; DASS 
Stress 
Dysfunctional Negative Emotions 
(RC7) 
 Major Depressive Disorder; Bipolar Disorder; DASS Depression; DASS 
Anxiety; DASS Stress 
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Aberrant Experiences (RC8)  Poor Physical Ability; Substance Use; Major Depressive Disorder; Somatoform 
Disorder; Bipolar Disorder; Post-Traumatic Stress Disorder; PDI Self-Care; 
PDI Life Support; DASS Depression; DASS Anxiety; DASS Stress 
Hypomanic Activation (RC9)  Substance Use; Post-Traumatic Stress Disorder; DASS Stress 
Specific Problems   
Malaise (MLS)  Hours Resting per Day; Major Depressive Disorder; PDI Total Score; PDI 
Family/Home; PDI Recreation; PDI Socialization; PDI Occupation; PDI Self-
Care; PDI Life Support; DASS Depression; DASS Anxiety; DASS Stress 
Gastrointestinal Complaints (GIC)  Poor Physical Ability (-); Major Depressive Disorder; DASS Anxiety; DASS 
Stress 
Head Pain Complaints (HPC)  Number of Narcotic Pain Medications (-); Major Depressive Disorder; PDI 
Total Score; PDI Life Support; DASS Anxiety 
Neurological Complaints (NUC)  Pain Intensity Rating; Number of Benzodiazepines; Hours Resting per Day; 
PDI Total Score; PDI Family/Home; PDI Recreation; PDI Occupation; PDI 
Sexual; PDI Self-Care; PDI Life Support; DASS Depression; DASS Anxiety; 
Number of Stairs Climbed in One Minute (-); Functional Reach in Inches (-); 
University of Alabama Pain Behavior Rating Scales Total Score; 
Cognitive Complaints (COG)  Major Depressive Disorder; PDI Total Score; DASS Depression; DASS 
Anxiety; DASS Stress 
Suicidal Ideation (SUI)  Hours Resting per Day; Substance Use; Major Depressive Disorder; PDI 
Total Score; PDI Sexual; DASS Depression; DASS Anxiety 
Helplessness (HLP)  Pain Disability; Hours Resting per Day; Major Depressive Disorder; DASS 
Depression; DASS Anxiety 
Self-Doubt (SFD)  Number of Antidepressants; Hours Resting per Day; Major Depressive 
Disorder; DASS Depression; DASS Anxiety; DASS Stress 
Inefficacy (NFC)  Major Depressive Disorder; DASS Depression; DASS Anxiety; DASS Stress; 
Stress/Worry (STW)  Pain Disability (-); Number of Antidepressants; Number of Antipsychotics; 
Number of Benzodiazepines; Major Depressive Disorder; Anxiety Disorder; 
DASS Depression; DASS Anxiety; DASS Stress 
Anxiety (AXY)  Number of Antidepressants; Number of Antipsychotics; Number of 
Benzodiazepines; Substance Use; Major Depressive Disorder; Anxiety 
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Disorder; Bipolar Disorder; Post-Traumatic Stress Disorder; DASS Depression; 
DASS Anxiety; DASS Stress 
Anger Proneness (ANP)  Major Depressive Disorder; DASS Depression; DASS Anxiety; DASS Stress 
Behavior Restricting Fears (BRF)  Major Depressive Disorder; DASS Depression; DASS Anxiety; Functional 
Reach in Inches (-) 
Multiple Specific Fears (MSF)  Substance Use (-); Number of Stairs Climbed in One Minute (-); Functional 
Reach in Inches (-) 
Juvenile Conduct Problems (JCP)  Current Smoker; Substance Use; Bipolar Disorder; Post-Traumatic Stress 
Disorder 
Substance Abuse (SUB)  Current Smoker; Substance Use; PDI Family/Home (-); PDI Recreation (-) 
Aggression (AGG)  Substance Use; Bipolar Disorder; Post-Traumatic Stress Disorder; DASS 
Depression; DASS Stress 
Activation (ACT)  DASS Anxiety; DASS Stress 
Family Problems (FML)  Major Depressive Disorder; Bipolar Disorder; DASS Stress 
Interpersonal Passivity (IPP)  N/A 
Social Avoidance (SAV)  N/A 
Shyness (SHY)  N/A 
Disaffiliativeness (DSF)  Current Smoker; Substance Use; Bipolar Disorder; DASS Depression 
Aesthetic-Literary Interests (AES)  N/A 
Mechanical-Physical Interests (MEC)  Substance Use 
Personality-Psychopathology-5   
Aggressiveness-Revised (AGGR-r)  N/A 
Psychoticism-Revised (PSYC-r)  Poor Physical Ability; Pain Disability; Substance Use; Major Depressive 
Disorder; Somatoform Disorder; Bipolar Disorder; Post-Traumatic Stress 
Disorder; PDI Self-Care; DASS Depression; DASS Anxiety; DASS Stress; 
Disconstraint-Revised (DISC-r)  Current Smoker; Substance Use; Post-Traumatic Stress Disorder; PDI 
Family/Home (-); Functional Reach in Inches 
Negative Emotionality/Neuroticism-
Revised (NEGE-r) 
 Pain Disability (-); Number of Antidepressants; Number of Antipsychotics; 
Number of Benzodiazepines; Major Depressive Disorder; DASS Depression; 
DASS Anxiety; DASS Stress 
Introversion/Low Positive  Pain Disability; Hours Resting per Day; Major Depressive Disorder; PDI 
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Emotionality-Revised (INTR-r) Total Score; PDI Socialization; PDI Occupation 
Note. Italics indicate criterion is an outcome variable. Underline indicates highest correlated criterion. Bold indicates 
highest correlated criterion (non-self-report). N/A (Not Applicable). (-) (negative correlation). 
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Table 15. MMPI-2-RF Scale Interpretations for this Setting 
Scale  Interpretations 
Higher-Order   
Emotional/Internalizing Dysfunction 
(EID) 
      This 41-item scale has items describing general mood and anxiety 
pathology, and it functions as a dimensional counterpart to the MMPI-2 27/72 
code type. In this sample it was associated with pain disability, broadly defined, 
as well as hours resting per day, duration of pain, and major depressive 
disorder. 
Thought Dysfunction (THD)       This 26-item scale is a broad measure of symptoms associated with 
disordered thinking, and it functions as a dimensional counterpart to the MMPI-
2 68/86 code type. In this sample it was correlated with somatoform disorder 
diagnosis. 
Behavioral/Externalizing Dysfunction 
(BXD) 
      This 23-item scale has items describing a broad range of externalizing 
problems, such as substance abuse, aggression, and antisocial behavior. It is 
functionally similar to the MMPI-2 49/94 code type, but as a dimensional 
measure. In this sample it was associated with pain disability in the family 
environment and substance use disorder. 
Restructured Clinical   
Demoralization (RCd)       This 24-item scale has items describing unhappiness and dissatisfaction with 
life. In this sample it was correlated with pain disability, broadly defined, as 
well as hours resting per day and major depressive disorder. 
Somatic Complaints (RC1)       This 27-item scale has items describing a variety of somatic complaints that 
may reflect genuine health issues. In this sample it was associated with pain 
intensity, hours resting per day, somatoform disorder, pain disability in a 
variety of contexts, and major depressive disorder diagnosis. 
Low Positive Emotions (RC2)       This 17-item scale primarily has items describing anhedonic features 
typically associated with depression.  In this sample it was associated with 
hours resting per day, pain disability, and major depressive disorder. 
Cynicism (RC3)       This 15-item scale has items describing the propensity to view the world in a 
negative light. For example, individuals scoring high on this scale may report 
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that people cannot be trusted. In this sample RC3 was associated with bipolar 
disorder. 
Antisocial Behavior (RC4)       This 22-item scale has items describing antisocial behaviors such as 
substance use, failure to conform, juvenile delinquency, aggressiveness, and 
impulsivity. In this sample it was correlated with substance use disorder 
diagnosis. 
Persecutory Ideation (RC6)       This 17-item scale has items describing persecutory beliefs which reflect 
extreme notions that the test-taker is being targeted (e.g., subject to being 
followed, poisoned, etc.). In this sample it was associated with PTSD. 
Dysfunctional Negative Emotions 
(RC7) 
      This 24-item scale has items describing negative emotions, including 
anxiety, anger, and fear. In the current sample it was associated with major 
depressive disorder diagnosis. 
Aberrant Experiences (RC8)       This 18-item scale has items describing disordered thinking characterized by 
unusual beliefs and perceptions. In the current sample it was associated with 
somatoform disorder and pain disability in the domain of basic care. It was also 
associated with poor physical ability outcomes at discharge. 
Hypomanic Activation (RC9)       This 28-item scale has items describing hypomanic behavior such as 
heightened mood, racing thoughts, increased energy, and sensation seeking. In 
the current sample it was associated with substance use disorder diagnosis. 
Specific Problems   
Malaise (MLS)       This eight-item scale has items describing feelings that one is in poor health. 
In the current sample it was associated with hours resting per day and pain 
disability in most contexts. 
Head Pain Complaints (HPC)       This six-item scale has items describing complaints of head and neck pain, 
including headaches. In the current sample it was associated with major 
depressive disorder and pain disability, broadly defined. 
Neurological Complaints (NUC)       This 10-item scale has items describing neurological complaints such as 
dizziness, numbness, and involuntary movement. In this sample it was 
correlated with pain disability in nearly all contexts, pain intensity, hours 
resting per day, poor physical ability at intake, and number of pain behaviors.   
Cognitive Complaints (COG)       This 10-item scale has items describing cognitive complaints such as 
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memory issues, concentration problems, and confusion. In this sample it was 
associated with pain disability, broadly defined, and major depressive disorder. 
Suicidal Ideation (SUI)       This five-item scale has items describing recent suicidal ideation or 
attempts. In this sample it was associated with hours resting per day, pain 
disability, and major depressive disorder diagnosis. 
Helplessness (HLP)       This five-item scale has items describing beliefs that one is incapable of 
changing their current problems. In this sample it was associated with hours 
resting per day, major depressive disorder, and worse pain disability outcomes. 
Self-Doubt (SFD)       This four-item scale has items describing poor self-confidence and a sense 
of uselessness. In the current sample it was associated with major depressive 
disorder and hours resting per day. 
Inefficacy (NFC)       This nine-item scale has items describing beliefs that one is indecisive and 
incapable of effectively dealing with common problems. In this sample it was 
correlated with major depressive disorder. 
Stress/Worry (STW)       This seven-item scale has items describing general worries as well as 
preoccupation with disappointment. In the current sample it was associated with 
less pain disability at discharge, major depressive disorder, and anxiety 
disorders. 
Anxiety (AXY)       This five-item scale has items describing significant anxiety, including 
intrusive ideation, sleep problems, and post-traumatic distress. In this sample it 
was correlated with major depressive disorder and PTSD. 
Anger Proneness (ANP)       This seven-item scale has items describing a propensity to anger easily and 
be inpatient with others. In this sample it was associated with major depressive 
disorder diagnosis. 
Behavior Restricting Fears (BRF)       This nine-item scale has items describing fears of leaving home and open 
spaces, as well as other situations that restrict their normal activity. In this 
sample it was associated with major depressive disorder and worse physical 
ability. 
Multiple Specific Fears (MSF)       This nine-item scale has items describing a variety of fears, including fears 
of animals and acts of nature. In this sample it was correlated with worse 
physical ability in terms of number of stairs climbed in one minute and 
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functional reach. 
Juvenile Conduct Problems (JCP)       This six-item scale has items describing problem behaviors as a juvenile, 
including stealing, being negatively influenced by peers, and behavior problems 
at school. In the current sample it was associated with substance use disorder 
diagnosis. 
Substance Abuse (SUB)       This seven-item scale has items describing past and current substance abuse. 
In the current study it was associated with substance use disorder, as well as 
less reported pain disability. 
Aggression (AGG)       This nine-item scale measures physically aggressive behavior. In this sample 
it was associated with substance use disorder. 
Family Problems (FML)       This scale has 10 items describing a variety of conflict in one’s family 
relationships. In this sample it was associated with major depressive disorder. 
Personality-Psychopathology-5   
Psychoticism-Revised (PSYC-r)       This 26-item scale measures a variety of thought disturbance symptoms. In 
this sample it was correlated with worse physical ability and pain disability 
outcomes, as well as somatoform disorder and intake pain disability in the self-
care domain. 
Disconstraint-Revised (DISC-r)       This 20-item scale has items describing various impulsive behaviors. In this 
sample it was associated with substance use disorder. 
Negative Emotionality/Neuroticism-
Revised (NEGE-r) 
      This 20-item scale has items describing a variety of negative emotional 
experiences, including anxiety, worry, and preoccupation with disappointment. 
In this sample it was associated with better pain disability outcomes, as well as 
major depressive disorder diagnosis. 
Introversion/Low Positive 
Emotionality-Revised (INTR-r) 
      This 20-item scale has items describing the tendency to avoid social 
situations and decreased propensity for experiencing positive emotional 
experiences. In this sample it was associated with worse pain disability 
outcomes, as well as hours resting per day, pain disability at intake, and major 
depressive disorder. 
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A series of analyses were conducted to investigate the interpretive utility of the 
RC Scales compared to the MMPI-2’s Clinical Scales. Mean profile comparisons were 
generally consistent with hypotheses. The depressed group produced clinically significant 
mean elevations on RCd, RC1, and RC2, whereas Clinical Scale elevations were 
observed on scales 1, 2, 3, and 7, with a near elevation on scale 8. These results were 
consistent with the findings of McCord and Drerup (2011), except scale 4 was not 
elevated in the current study. The depressed group in those authors’ study was more 
heterogeneous, as it included individuals with comorbid mental disorders, which may 
account for this difference. In the substance use group, the hypotheses were partially 
supported. Though this group produced clinically significant mean elevations on RC1 and 
Clinical Scales 1, 2, and 3, with a near elevation on scale 4, there were no elevations on 
RC4 or Clinical Scales 8 or 9. However, the RC scales do provide an improved 
diagnostic profile compared to the Clinical Scales, which produced an unexpected mean 
elevation on Clinical Scale 7 and meaningfully higher scores on scales 2, 6, and 8 
compared to their RC scale counterparts. In the no diagnosis group, the hypotheses were 
fully supported, with the group producing elevations on RC1 and Clinical Scales 1, 2, and 
3. This Clinical Scale pattern has been referred to as the conversion-v, which was 
predominant among pain patients. These results provide some indication that the three-
scale conversion-v is more parsimoniously described by a single RC Scale elevation 
(RC1). Moreover, though not included in the comparisons, RC1 has five associated 
Somatic/Cognitive Specific Problems scales to further clarify interpretation.  
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Elevation rates across the two scale sets were consistent with the mean profile 
analyses and highlight the practical implications of the results. Clinical scale elevation 
rates were significantly higher than RC Scale elevation rates in over one-quarter of the 
comparisons, with no instances of significantly higher RC scale elevation rates. Clinical 
Scale elevation rates were particularly concerning in the no diagnosis group. For 
example, 67 percent of the group elevated at 65T on scale 2 and 31 percent elevated at 
80T. Additionally, 29 percent produced elevations on scale 4 and 26 percent had 
elevations on scale 8. These results suggest that a meaningful minority of patients with no 
identifiable mental disorder could be described as severely depressed, antisocial, and 
psychotic according to Clinical Scale interpretations. These findings highlight the poor 
discriminant validity of the Clinical Scales, which were highlighted in the MMPI-2 
literature reviewed in the introduction (Helmes & Reddon, 1993; Main & Spanswick, 
1995; McCord & Drerup, 2011; Turk & Fernandez, 1995).  
Mean profile comparisons across diagnoses by scale set also indicate that the RC 
Scales have improved discriminant validity, a major emphasis in their development. The 
RC Scale comparisons were straightforward and consistent with theoretical expectations, 
with the depressed group scoring highest on RCd, RC1, RC2, and RC7, the substance use 
group scoring highest on RC4, and all groups producing approximately equal scores on 
RC3, RC6, RC8, and RC9. In comparison, the Clinical Scales produced a muddled 
pattern of differences across groups. Indeed, though the depressed group had significantly 
higher scores on scale 2 than the other groups, they also had higher scores on scale 8. The 
depressed group scored significantly higher than the no diagnosis group on Clinical 
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Scales 6 and 7, but not higher than the substance use group. Finally, the substance use 
group scored significantly higher than the no diagnosis group on Clinical Scale 4, but not 
the depressed group. The pattern of elevation rates across diagnoses by scale set were 
fairly similar, though RC2, RC4, and RC8 demonstrated improved discrimination 
compared to the corresponding Clinical Scales.  
 Overall, the results indicate that the Restructured Clinical Scales have improved 
interpretive utility compared to the Clinical Scales. As previously described, the MMPI-
2-RF additionally includes a set of 23 Specific Problems Scales and the five revised 
Personality-Psychopathology-5 (PSY-5) scales. These scales can likely further aid 
interpretation of the RC Scales, as some of the Specific Problem Scales were designed to 
measure narrow RC scale subdomains, as well as other narrow constructs associated with 
the RC Scale constructs, and the revised PSY-5 scales measure personality constructs 
associated with the RC Scales.  
 
Summary, Limitations, and Future Directions 
 Taken as a whole, the results of this study support the use of the MMPI-2-RF 
among chronic low back pain patients. The scales generally demonstrated adequate 
reliability consistent with the normative sample, especially when standard error of 
measurement information is considered. Most domains showed evidence for convergent 
and discriminant validity in this setting, including the Internalizing, Thought 
Dysfunction, and Somatic/Cognitive Functioning domains. Moreover, these domains 
demonstrated utility in predicting relevant chronic pain outcomes, a finding that has 
generally eluded researchers using the MMPI-2.  
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 These promising findings notwithstanding, several limitations and areas for future 
research are indicated. The sample only included patients presenting with chronic low 
back pain. Though this is the most common complaint of individuals in chronic pain 
settings, it would be useful to see whether these findings generalize to other conditions, 
such as fibromyalgia, chronic fatigue syndrome, migraine headaches, multiple sclerosis, 
and other neurological disorders. Furthermore, replication of these results in other 
settings is necessary, as this study investigates outcomes among patients in a structured 
multi-disciplinary pain treatment program. Though such a program is recommended for 
chronic pain patients, it is likely not representative of the treatment received by the 
majority of pain patients. Finally, investigating the test’s association with other indicators 
of outcome would be beneficial and may provide additional insight into the utility of the 
MMPI-2-RF in assessment of among chronic low back pain patients. Specifically, given 
the previously mentioned high rates comorbidity of mood disorders, it would be desirable 
to determine how the test predicts reduction in these symptoms. The Externalizing scales 
may also be useful in the prediction of treatment and appointment non-adherence, as well 
as long-term narcotic medication usage.   
 This study also has at least some degree of criterion contamination, as MMPI-2 
scores were available to clinicians who made diagnostic judgments and treatment 
recommendations. Though the MMPI-2 was re-scored to provide MMPI-2-RF scale 
scores for the entire sample, the tests have the same items. Moreover, the clinicians had 
access to the Restructured Clinical Scale scores in a majority of cases, as the data 
collection was mostly completed after their release. This study characteristic is 
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particularly limiting for the RC/Clinical Scale comparison, as clinicians may have 
interpreted the test using both sets of scales. More generally, clinicians likely varied in 
their approach to diagnosis, which makes it difficult to assess the impact of criterion 
contamination.  
 
Conclusion 
 These limitations notwithstanding, the results of the current study support the 
reliability and predictive validity of the MMPI-2-RF among chronic low back pain 
patients, as well as improved clinical utility relative to the MMPI-2 Clinical Scales. 
These findings suggest that the test is appropriate for use in chronic pain settings, though 
replication and future research with other pain conditions is warranted.  
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